Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
Term:quinazolines
go back to main search page
Accession:CHEBI:38530 term browser browse the term
Definition:Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.
Synonyms:alt_id: MESH:D011799
 xref_mesh: MESH:D011799


show annotations for term's descendants           Sort by:
quinazolines term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aurka aurora kinase A affects splicing ISO Quinazolines affects the splicing of AURKA mRNA CTD PMID:25281741 NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390 		JBrowse link
G Avpr1b arginine vasopressin receptor 1B multiple interactions ISO Quinazolines analog binds to and results in decreased activity of AVPR1B protein CTD PMID:20719508 NCBI chr13:43,046,531...43,059,046
Ensembl chr13:43,046,267...43,057,792 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO Quinazolines inhibits the reaction [Pt(O,O'-acac)(gamma-acac)(DMS) results in increased expression of BAX protein] CTD PMID:21420390 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO Quinazolines inhibits the reaction [Pt(O,O'-acac)(gamma-acac)(DMS) results in decreased expression of BCL2 protein] CTD PMID:21420390 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Brd2 bromodomain containing 2 decreases splicing ISO Quinazolines results in decreased splicing of BRD2 mRNA CTD PMID:25281741 NCBI chr20:4,727,078...4,735,389
Ensembl chr20:4,728,151...4,735,388 		JBrowse link
G Ccna2 cyclin A2 affects splicing ISO Quinazolines affects the splicing of CCNA2 mRNA CTD PMID:25281741 NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B affects splicing ISO Quinazolines affects the splicing of CDKN1B mRNA CTD PMID:25281741 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982 		JBrowse link
G Egfr epidermal growth factor receptor multiple interactions
decreases phosphorylation		 ISO Quinazolines analog inhibits the reaction [EGFR protein results in increased activity of MAPK1 protein]; Quinazolines analog inhibits the reaction [EGFR protein results in increased activity of MAPK3 protein]
Quinazolines analog results in decreased phosphorylation of EGFR protein		 CTD PMID:10753475 PMID:21075094 NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 decreases phosphorylation ISO Quinazolines analog results in decreased phosphorylation of ERBB2 protein CTD PMID:10753475 NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078 		JBrowse link
G Gper1 G protein-coupled estrogen receptor 1 multiple interactions EXP Quinazolines inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 protein] CTD PMID:22645130 NCBI chr12:15,217,217...15,222,679
Ensembl chr12:15,217,442...15,221,889 		JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO Quinazolines inhibits the reaction [IL33 protein results in increased expression of IL1B mRNA]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of IL1B protein] CTD PMID:23585867 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il33 interleukin 33 multiple interactions ISO Quinazolines inhibits the reaction [IL33 protein results in increased expression of CXCL8 mRNA]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of CXCL8 protein]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of IL1B mRNA]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of IL1B protein]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of IL6 mRNA]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of IL6 protein]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of TNF mRNA]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of TNF protein]; Quinazolines inhibits the reaction [IL33 protein results in increased phosphorylation of and results in increased localization of and results in increased activity of RELA protein] CTD PMID:23585867 NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO Quinazolines inhibits the reaction [IL33 protein results in increased expression of IL6 mRNA]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of IL6 protein] CTD PMID:23585867 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Kdr kinase insert domain receptor multiple interactions ISO Quinazolines analog binds to and results in decreased activity of KDR protein CTD PMID:16302797 NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO Quinazolines analog inhibits the reaction [EGFR protein results in increased activity of MAPK1 protein] CTD PMID:21075094 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO Quinazolines analog inhibits the reaction [EGFR protein results in increased activity of MAPK3 protein] CTD PMID:21075094 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member affects splicing ISO Quinazolines affects the splicing of MCL1 mRNA CTD PMID:25281741 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO Quinazolines inhibits the reaction [IL33 protein results in increased phosphorylation of and results in increased localization of and results in increased activity of RELA protein] CTD PMID:23585867 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Riok3 RIO kinase 3 decreases splicing ISO Quinazolines results in decreased splicing of RIOK3 mRNA CTD PMID:25281741 NCBI chr18:3,327,776...3,353,350
Ensembl chr18:3,327,776...3,353,343 		JBrowse link
G Slc1a2 solute carrier family 1 member 2 multiple interactions EXP Quinazolines inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 protein] CTD PMID:22645130 NCBI chr 3:89,005,129...89,135,469
Ensembl chr 3:89,005,129...89,126,498 		JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO Quinazolines inhibits the reaction [IL33 protein results in increased expression of TNF mRNA]; Quinazolines inhibits the reaction [IL33 protein results in increased expression of TNF protein] CTD PMID:23585867 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tyms thymidylate synthetase decreases activity ISO Quinazolines analog results in decreased activity of TYMS protein CTD PMID:2909728 NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536 		JBrowse link
afatinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO AKT1 protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein] CTD PMID:36460225 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO [CALM2 protein affects the susceptibility to Afatinib] which affects the expression of BAX protein; BAX protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein] CTD PMID:36460225 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bbc3 Bcl-2 binding component 3 multiple interactions ISO BBC3 protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein] CTD PMID:36460225 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509 		JBrowse link
G Calm2 calmodulin 2 multiple interactions
affects response to substance		 ISO [CALM2 protein affects the susceptibility to Afatinib] which affects the expression of BAX protein; [CALM2 protein affects the susceptibility to Afatinib] which affects the localization of DIABLO protein; [CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein; AKT1 protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein]; BAX protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein]; BBC3 protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein]; MCL1 protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein] CTD PMID:36460225 NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287
Ensembl chr15:7,091,567...7,104,287 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO [CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein; AKT1 protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein]; BAX protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein]; BBC3 protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein]; MCL1 protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein] CTD PMID:36460225 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Diablo diablo, IAP-binding mitochondrial protein multiple interactions ISO [CALM2 protein affects the susceptibility to Afatinib] which affects the localization of DIABLO protein CTD PMID:36460225 NCBI chr12:33,055,784...33,070,401
Ensembl chr12:33,055,263...33,070,387 		JBrowse link
G Egf epidermal growth factor multiple interactions ISO afatinib inhibits the reaction [EGF protein results in increased expression of EHMT2 protein]; afatinib inhibits the reaction [EGF protein results in increased expression of POU5F1 protein] CTD PMID:28787001 NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064 		JBrowse link
G Egfr epidermal growth factor receptor decreases activity
decreases phosphorylation		 ISO afatinib results in decreased activity of EGFR protein; afatinib results in decreased activity of EGFR protein mutant form
afatinib results in decreased phosphorylation of EGFR protein		 CTD PMID:21322567 PMID:22242139 PMID:28787001 NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Ehmt2 euchromatic histone lysine methyltransferase 2 multiple interactions ISO afatinib inhibits the reaction [EGF protein results in increased expression of EHMT2 protein] CTD PMID:28787001 NCBI chr20:3,919,623...3,936,751
Ensembl chr20:3,919,624...3,941,547 		JBrowse link
G Ikbkb inhibitor of nuclear factor kappa B kinase subunit beta decreases expression ISO afatinib results in decreased expression of IKBKB protein CTD PMID:22242139 NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250 		JBrowse link
G Iqgap1 IQ motif containing GTPase activating protein 1 decreases phosphorylation ISO Afatinib results in decreased phosphorylation of IQGAP1 protein CTD PMID:33087447 NCBI chr 1:134,679,581...134,769,776
Ensembl chr 1:134,679,586...134,769,755 		JBrowse link
G Ldha lactate dehydrogenase A increases secretion ISO Afatinib results in increased secretion of LDHA protein CTD PMID:37660997 NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member multiple interactions ISO MCL1 protein affects the reaction [[CALM2 protein affects the susceptibility to Afatinib] which results in increased cleavage of CASP3 protein] CTD PMID:36460225 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303 		JBrowse link
G Muc5ac mucin 5AC, oligomeric mucus/gel-forming multiple interactions ISO Afatinib inhibits the reaction [[Smoke results in increased abundance of Particulate Matter] which results in increased expression of MUC5AC mRNA] CTD PMID:31944254 NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 multiple interactions ISO afatinib results in decreased activity of [RELA protein binds to NFKB1 protein] CTD PMID:22242139 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404 		JBrowse link
G Pou5f1 POU class 5 homeobox 1 decreases expression
multiple interactions		 ISO afatinib results in decreased expression of POU5F1 protein
afatinib inhibits the reaction [EGF protein results in increased expression of POU5F1 protein]		 CTD PMID:28787001 NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO afatinib results in decreased activity of [RELA protein binds to NFKB1 protein] CTD PMID:22242139 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Set Set nuclear proto-oncogene affects localization ISO Afatinib affects the localization of SET protein alternative form CTD PMID:36534342 NCBI chr 3:13,334,564...13,345,598
Ensembl chr 3:13,335,041...13,363,567 		JBrowse link
alfuzosin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adra1a adrenoceptor alpha 1A affects binding
multiple interactions		 EXP
ISO		 alfuzosin binds to ADRA1A protein
alfuzosin inhibits the reaction [Prazosin binds to ADRA1A protein]		 CTD PMID:7536677 PMID:8183249 PMID:8196478 PMID:21544540 NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500 		JBrowse link
G Adra1b adrenoceptor alpha 1B affects binding ISO alfuzosin binds to ADRA1B protein CTD PMID:8183249 NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919 		JBrowse link
G Adra1d adrenoceptor alpha 1D affects binding ISO
EXP		 alfuzosin binds to ADRA1D protein CTD PMID:8183249 PMID:9294627 NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions EXP alfuzosin inhibits the reaction [Cyclophosphamide results in increased expression of FOS protein] CTD PMID:17240043 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036 		JBrowse link
G Gnrh1 gonadotropin releasing hormone 1 multiple interactions EXP alfuzosin inhibits the reaction [Phenylephrine results in decreased secretion of GNRH1 protein]; alfuzosin inhibits the reaction [Phenylephrine results in increased secretion of GNRH1 protein] CTD PMID:1975657 NCBI chr15:41,972,482...41,976,690
Ensembl chr15:41,972,905...41,973,581
Ensembl chr15:41,972,905...41,973,581 		JBrowse link
G Tac1 tachykinin, precursor 1 multiple interactions EXP alfuzosin inhibits the reaction [Phenylephrine results in increased secretion of TAC1 protein] CTD PMID:17240043 NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178 		JBrowse link
Anhydrotetrodotoxin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Scn8a sodium voltage-gated channel alpha subunit 8 decreases activity ISO anhydrotetrodotoxin results in decreased activity of SCN8A protein CTD PMID:17522141 NCBI chr 7:131,982,152...132,156,075
Ensembl chr 7:131,982,480...132,151,292 		JBrowse link
ARS-1620 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation ISO ARS-1620 results in decreased phosphorylation of AKT1 protein CTD PMID:31332011 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Kras KRAS proto-oncogene, GTPase affects binding ISO ARS-1620 binds to KRAS protein mutant form CTD PMID:31666701 NCBI chr 4:178,185,418...178,218,484 JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation ISO ARS-1620 results in decreased phosphorylation of MAPK1 protein CTD PMID:31332011 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation ISO ARS-1620 results in decreased phosphorylation of MAPK3 protein CTD PMID:31332011 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
canertinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Aifm1 apoptosis inducing factor, mitochondria associated 1 multiple interactions ISO Canertinib inhibits the reaction [Acetaminophen results in increased transport of AIFM1 protein] CTD PMID:28123000 NCBI chr  X:127,650,223...127,689,356
Ensembl chr  X:127,650,226...127,689,256 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO Canertinib inhibits the reaction [Acetaminophen promotes the reaction [[CCND1 protein binds to and results in increased activity of CDK4 protein] which results in increased phosphorylation of RB1 protein]]; Canertinib inhibits the reaction [Acetaminophen results in increased expression of CCND1 protein] CTD PMID:28123000 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Cdk4 cyclin-dependent kinase 4 multiple interactions ISO Canertinib inhibits the reaction [Acetaminophen promotes the reaction [[CCND1 protein binds to and results in increased activity of CDK4 protein] which results in increased phosphorylation of RB1 protein]]; Canertinib inhibits the reaction [Acetaminophen results in increased expression of CDK4 protein] CTD PMID:28123000 NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403 		JBrowse link
G Egf epidermal growth factor multiple interactions ISO Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of ERBB2 protein]; Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] CTD PMID:18927496 NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064 		JBrowse link
G Egfr epidermal growth factor receptor multiple interactions
decreases phosphorylation
decreases activity		 ISO Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]
Canertinib inhibits the reaction [Acetaminophen affects the localization of EGFR protein]; Canertinib inhibits the reaction [Acetaminophen results in increased phosphorylation of and results in increased activity of EGFR protein]
Canertinib results in decreased phosphorylation of EGFR protein
Canertinib results in decreased activity of EGFR protein; Canertinib results in decreased activity of EGFR protein mutant form		 CTD PMID:15956251 PMID:18927496 PMID:21322567 PMID:28123000 NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Endog endonuclease G multiple interactions ISO Canertinib inhibits the reaction [Acetaminophen results in increased transport of ENDOG protein] CTD PMID:28123000 NCBI chr 3:13,449,113...13,451,715
Ensembl chr 3:13,449,086...13,451,932 		JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions ISO Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of ERBB2 protein] CTD PMID:18927496 NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein] CTD PMID:18927496 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO Canertinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein] CTD PMID:18927496 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions ISO Canertinib inhibits the reaction [Acetaminophen promotes the reaction [[CCND1 protein binds to and results in increased activity of CDK4 protein] which results in increased phosphorylation of RB1 protein]]; Canertinib inhibits the reaction [Acetaminophen results in increased phosphorylation of RB1 protein] CTD PMID:28123000 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 decreases activity ISO Canertinib results in decreased activity of TGFB1 protein CTD PMID:31652400 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Vegfa vascular endothelial growth factor A decreases expression
decreases secretion		 ISO Canertinib results in decreased expression of VEGFA mRNA; Canertinib results in decreased expression of VEGFA protein
Canertinib results in decreased secretion of VEGFA protein		 CTD PMID:15956251 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
cyclazosin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adra1b adrenoceptor alpha 1B multiple interactions EXP cyclazosin binds to and results in decreased activity of ADRA1B protein CTD PMID:15951348 NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919 		JBrowse link
dacomitinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 multiple interactions
affects metabolic processing		 ISO Quinidine affects the reaction [CYP2D6 protein polymorphism affects the metabolism of dacomitinib] CTD PMID:34936353 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759 		JBrowse link
G Egfr epidermal growth factor receptor multiple interactions ISO dacomitinib inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] CTD PMID:27491023 NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
doxazosin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions ISO Doxazosin inhibits the reaction [ABCB1 protein results in increased transport of Digoxin] CTD PMID:11895100 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Adra1a adrenoceptor alpha 1A affects binding EXP
ISO		 Doxazosin binds to ADRA1A protein CTD PMID:7536677 PMID:8183249 PMID:21544540 NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500 		JBrowse link
G Adra1b adrenoceptor alpha 1B affects binding ISO Doxazosin binds to ADRA1B protein CTD PMID:8183249 NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919 		JBrowse link
G Adra1d adrenoceptor alpha 1D affects binding ISO
EXP		 Doxazosin binds to ADRA1D protein CTD PMID:8183249 PMID:9294627 NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354 		JBrowse link
G Adra2a adrenoceptor alpha 2A multiple interactions
decreases expression
increases activity		 ISO Doxazosin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]
Doxazosin results in decreased expression of ADRA2A protein
Doxazosin results in increased activity of ADRA2A protein		 CTD PMID:10694191 PMID:10742289 NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365 		JBrowse link
G Adrb1 adrenoceptor beta 1 increases expression EXP Doxazosin results in increased expression of ADRB1 protein CTD PMID:18084315 NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259 		JBrowse link
G Adrb2 adrenoceptor beta 2 increases expression EXP Doxazosin results in increased expression of ADRB2 protein CTD PMID:18084315 NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 affects phosphorylation EXP Doxazosin affects the phosphorylation of AKT1 protein CTD PMID:18084315 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression
multiple interactions		 ISO Doxazosin results in increased expression of BAX protein
SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of BAX protein]		 CTD PMID:16007219 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO BCL2 inhibits the reaction [Doxazosin results in decreased expression of VEGFA] CTD PMID:12576871 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Casp3 caspase 3 increases activity
multiple interactions		 ISO Doxazosin results in increased activity of CASP3 protein
Doxazosin results in increased cleavage of and results in increased activity of CASP3 protein		 CTD PMID:12771931 PMID:15221243 PMID:22845314 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Ccna2 cyclin A2 decreases expression ISO Doxazosin results in decreased expression of CCNA2 protein CTD PMID:15371785 NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression ISO Doxazosin results in increased expression of CDKN1A mRNA CTD PMID:12771931 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Col1a1 collagen type I alpha 1 chain multiple interactions EXP Doxazosin inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA] CTD PMID:19575289 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624 		JBrowse link
G Crp C-reactive protein decreases expression ISO Doxazosin results in decreased expression of CRP protein CTD PMID:16680063 NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression ISO Doxazosin results in increased expression of DDIT3 protein CTD PMID:22845314 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Epha2 Eph receptor A2 multiple interactions ISO [Doxazosin results in increased phosphorylation of and results in increased activity of EPHA2 protein] which results in increased phosphorylation of and results in increased activity of PTPN11 protein; Doxazosin results in increased phosphorylation of and results in increased activity of EPHA2 protein; Lithocholic Acid inhibits the reaction [Doxazosin results in increased phosphorylation of and results in increased activity of EPHA2 protein] CTD PMID:22845314 NCBI chr 5:153,605,644...153,634,115
Ensembl chr 5:153,605,644...153,634,117 		JBrowse link
G Faslg Fas ligand increases expression ISO Doxazosin results in increased expression of FASLG mRNA CTD PMID:12771931 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215 		JBrowse link
G Klf10 KLF transcription factor 10 increases expression ISO Doxazosin results in increased expression of KLF10 mRNA; Doxazosin results in increased expression of KLF10 protein CTD PMID:12771931 NCBI chr 7:69,467,658...69,473,726
Ensembl chr 7:69,465,619...69,473,994 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 affects phosphorylation EXP Doxazosin affects the phosphorylation of MAPK1 protein CTD PMID:18084315 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 affects phosphorylation EXP Doxazosin affects the phosphorylation of MAPK3 protein CTD PMID:18084315 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mstn myostatin decreases expression EXP Doxazosin results in decreased expression of MSTN mRNA; Doxazosin results in decreased expression of MSTN protein CTD PMID:16968467 NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933 		JBrowse link
G Nfkbia NFKB inhibitor alpha increases expression ISO Doxazosin results in increased expression of NFKBIA mRNA; Doxazosin results in increased expression of NFKBIA protein CTD PMID:12771931 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Nppb natriuretic peptide B increases expression
multiple interactions		 ISO
EXP		 Doxazosin results in increased expression of NPPB protein
[Atenolol co-treated with Doxazosin] results in decreased expression of NPPB mRNA; [Atenolol co-treated with Losartan co-treated with Doxazosin] results in decreased expression of NPPB mRNA; [Losartan co-treated with Doxazosin] results in decreased expression of NPPB mRNA		 CTD PMID:15969258 PMID:18551024 NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168 		JBrowse link
G Ptk2 protein tyrosine kinase 2 decreases expression
increases cleavage		 ISO Doxazosin results in decreased expression of PTK2 protein
Doxazosin results in increased cleavage of PTK2 protein		 CTD PMID:15221243 PMID:22845314 NCBI chr 7:105,126,725...105,331,848
Ensembl chr 7:105,126,728...105,331,783 		JBrowse link
G Ptpn11 protein tyrosine phosphatase, non-receptor type 11 multiple interactions ISO [Doxazosin results in increased phosphorylation of and results in increased activity of EPHA2 protein] which results in increased phosphorylation of and results in increased activity of PTPN11 protein CTD PMID:22845314 NCBI chr12:35,365,436...35,424,925
Ensembl chr12:35,383,144...35,424,925 		JBrowse link
G Rb1 RB transcriptional corepressor 1 affects phosphorylation
decreases phosphorylation		 EXP
ISO		 Doxazosin affects the phosphorylation of RB1 protein
Doxazosin results in decreased phosphorylation of RB1 protein		 CTD PMID:15371785 PMID:18084315 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302 		JBrowse link
G Ren renin increases expression ISO Doxazosin results in increased expression of REN protein CTD PMID:7818152 NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489 		JBrowse link
G Serpinb5 serpin family B member 5 multiple interactions
increases response to substance		 ISO SERPINB5 protein promotes the reaction [Doxazosin results in decreased expression of VEGFA mRNA alternative form]; SERPINB5 protein promotes the reaction [Doxazosin results in decreased expression of VEGFA protein]; SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of BAX protein]; SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of SMAD4 mRNA]; SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of SMAD4 protein]
SERPINB5 protein results in increased susceptibility to Doxazosin		 CTD PMID:16007219 NCBI chr13:22,985,557...23,005,756
Ensembl chr13:22,985,557...23,005,756 		JBrowse link
G Slc22a2 solute carrier family 22 member 2 multiple interactions ISO Doxazosin inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] CTD PMID:21599003 NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268 		JBrowse link
G Smad4 SMAD family member 4 increases expression
multiple interactions		 ISO Doxazosin results in increased expression of SMAD4 mRNA; Doxazosin results in increased expression of SMAD4 protein
SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of SMAD4 mRNA]; SERPINB5 protein promotes the reaction [Doxazosin results in increased expression of SMAD4 protein]		 CTD PMID:12771931 PMID:16007219 NCBI chr18:67,243,742...67,274,438
Ensembl chr18:67,243,742...67,274,438 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions
decreases expression		 ISO BCL2 inhibits the reaction [Doxazosin results in decreased expression of VEGFA]; SERPINB5 protein promotes the reaction [Doxazosin results in decreased expression of VEGFA mRNA alternative form]; SERPINB5 protein promotes the reaction [Doxazosin results in decreased expression of VEGFA protein]
Doxazosin results in decreased expression of VEGFA mRNA; Doxazosin results in decreased expression of VEGFA mRNA alternative form; Doxazosin results in decreased expression of VEGFA protein		 CTD PMID:12576871 PMID:16007219 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
erastin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Acrbp acrosin binding protein increases expression ISO erastin results in increased expression of ACRBP mRNA alternative form CTD PMID:35234341 NCBI chr 4:157,851,149...157,864,211
Ensembl chr 4:157,841,841...157,864,213 		JBrowse link
G Acsl4 acyl-CoA synthetase long-chain family member 4 increases expression
multiple interactions		 ISO erastin results in increased expression of ACSL4 protein
leonurine inhibits the reaction [erastin results in increased expression of ACSL4 protein]		 CTD PMID:38670420 NCBI chr  X:105,942,794...106,006,573
Ensembl chr  X:105,942,799...106,006,427 		JBrowse link
G Ahr aryl hydrocarbon receptor multiple interactions
affects response to substance		 ISO AHR protein affects the reaction [[indol-3-yl pyruvic acid co-treated with erastin] results in increased expression of SLC7A11 protein]; AHR protein affects the reaction [erastin results in increased expression of SLC7A11 mRNA]; AHR protein affects the reaction [erastin results in increased expression of SLC7A11 protein]
AHR protein affects the susceptibility to erastin		 CTD PMID:38641223 NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568 		JBrowse link
G Arid3a AT-rich interaction domain 3A multiple interactions
increases expression		 ISO Doxycycline promotes the reaction [erastin results in increased expression of ARID3A mRNA] CTD PMID:38115220 NCBI chr 7:9,755,291...9,781,260
Ensembl chr 7:9,755,294...9,780,599 		JBrowse link
G Atf4 activating transcription factor 4 multiple interactions
increases expression		 ISO leonurine inhibits the reaction [erastin results in increased expression of ATF4 protein] CTD PMID:38670420 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Atg5 autophagy related 5 increases expression EXP erastin results in increased expression of ATG5 protein CTD PMID:32937103 NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209 		JBrowse link
G Bgn biglycan multiple interactions
decreases expression		 ISO BGN mRNA alternative form inhibits the reaction [erastin results in decreased expression of MKI67 protein]; erastin inhibits the reaction [[Antineoplastic Agents, Immunological results in decreased susceptibility to Antineoplastic Agents, Immunological] which results in increased expression of BGN mRNA alternative form]
erastin results in decreased expression of BGN mRNA alternative form		 CTD PMID:35234341 NCBI chr  X:151,197,296...151,209,458
Ensembl chr  X:151,197,273...151,209,461 		JBrowse link
G Casp3 caspase 3 multiple interactions
increases cleavage		 ISO 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide promotes the reaction [erastin results in increased cleavage of CASP3 protein] CTD PMID:38641223 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Cebpd CCAAT/enhancer binding protein delta increases expression
multiple interactions		 ISO erastin results in increased expression of CEBPD mRNA
Doxycycline promotes the reaction [erastin results in increased expression of CEBPD mRNA]		 CTD PMID:38115220 NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829 		JBrowse link
G Chac1 ChaC glutathione-specific gamma-glutamylcyclotransferase 1 multiple interactions
increases expression		 ISO GW 506033X inhibits the reaction [erastin results in increased expression of CHAC1 mRNA]
erastin results in increased expression of CHAC1 protein
leonurine inhibits the reaction [erastin results in increased expression of CHAC1 protein]		 CTD PMID:30817950 PMID:38670420 NCBI chr 3:106,342,302...106,345,526
Ensembl chr 3:106,342,302...106,345,526 		JBrowse link
G Chst4 carbohydrate sulfotransferase 4 increases expression
multiple interactions		 ISO erastin results in increased expression of CHST4 mRNA
Doxycycline promotes the reaction [erastin results in increased expression of CHST4 mRNA]		 CTD PMID:38115220 NCBI chr19:37,993,471...38,002,123
Ensembl chr19:37,991,417...38,003,608 		JBrowse link
G Cited2 Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 multiple interactions ISO [Doxycycline co-treated with erastin] results in increased expression of CITED2 mRNA CTD PMID:38115220 NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897 		JBrowse link
G Col1a2 collagen type I alpha 2 chain increases expression ISO erastin results in increased expression of COL1A2 mRNA alternative form CTD PMID:35234341 NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867 		JBrowse link
G Cyp2e1 cytochrome P450, family 2, subfamily e, polypeptide 1 multiple interactions ISO erastin affects the reaction [CYP2E1 protein affects the susceptibility to Ethanol] CTD PMID:33017621 NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 multiple interactions
increases expression		 ISO erastin promotes the reaction [Silicon Dioxide results in increased expression of DDIT3 protein]; GW 506033X inhibits the reaction [erastin results in increased expression of DDIT3 mRNA]
erastin results in increased expression of DDIT3 protein
leonurine inhibits the reaction [erastin results in increased expression of DDIT3 protein]		 CTD PMID:30817950 PMID:37075931 PMID:38670420 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Dtl denticleless E3 ubiquitin protein ligase homolog increases expression ISO erastin results in increased expression of DTL mRNA alternative form CTD PMID:35234341 NCBI chr13:103,115,810...103,155,029
Ensembl chr13:103,117,186...103,154,890 		JBrowse link
G Eif2ak3 eukaryotic translation initiation factor 2 alpha kinase 3 multiple interactions ISO erastin results in increased expression of and results in increased phosphorylation of EIF2AK3 protein; leonurine inhibits the reaction [erastin results in increased expression of EIF2AK3 protein] CTD PMID:38670420 NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911 		JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha multiple interactions ISO erastin results in increased expression of and results in increased phosphorylation of EIF2S1 protein; leonurine inhibits the reaction [erastin results in increased expression of and results in increased phosphorylation of EIF2S1 protein] CTD PMID:38670420 NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225 		JBrowse link
G Ern1 endoplasmic reticulum to nucleus signaling 1 multiple interactions
increases phosphorylation		 ISO GW 506033X inhibits the reaction [erastin results in increased phosphorylation of ERN1 protein] CTD PMID:30817950 NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029 		JBrowse link
G Fancd2 FA complementation group D2 decreases expression EXP erastin results in decreased expression of FANCD2 protein CTD PMID:32937103 NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412 		JBrowse link
G Fh fumarate hydratase decreases response to substance ISO FH protein results in decreased susceptibility to erastin CTD PMID:29917289 NCBI chr13:87,524,331...87,550,215
Ensembl chr13:87,524,337...87,550,266 		JBrowse link
G Fth1 ferritin heavy chain 1 multiple interactions
increases expression		 EXP
ISO		 3-methyladenine promotes the reaction [erastin results in increased expression of FTH1 protein]; Chloroquine promotes the reaction [erastin results in increased expression of FTH1 protein]; Deferiprone inhibits the reaction [erastin results in increased expression of FTH1 protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of FTH1 protein]
[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTH1 protein; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTH1 protein]; Chloroquine affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTH1 protein]		 CTD PMID:32937103 PMID:37951334 NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424 		JBrowse link
G Ftl1 ferritin light chain 1 multiple interactions ISO [PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTL protein; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTL protein]; Chloroquine affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTL protein] CTD PMID:37951334 NCBI chr 1:95,936,387...95,938,234
Ensembl chr 1:95,936,387...95,939,725
Ensembl chr10:95,936,387...95,939,725
Ensembl chr 2:95,936,387...95,939,725 		JBrowse link
G Gabarapl1 GABA type A receptor associated protein like 1 increases expression
multiple interactions		 ISO erastin results in increased expression of GABARAPL1 mRNA
Doxycycline promotes the reaction [erastin results in increased expression of GABARAPL1 mRNA]		 CTD PMID:38115220 NCBI chr 4:162,980,309...162,989,452
Ensembl chr 4:162,980,249...162,989,450 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions
increases expression		 EXP NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLC protein] CTD PMID:32937103 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Gclm glutamate cysteine ligase, modifier subunit increases expression
multiple interactions		 EXP erastin results in increased expression of GCLM protein
NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLM protein]		 CTD PMID:32937103 NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535 		JBrowse link
G Gja1 gap junction protein, alpha 1 multiple interactions ISO GJA1 protein affects the reaction [erastin results in decreased expression of GPX4 protein]; GJA1 protein affects the reaction [erastin results in decreased expression of SLC7A11 protein] CTD PMID:34785303 NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582 		JBrowse link
G Gpx4 glutathione peroxidase 4 decreases expression
multiple interactions		 ISO
EXP		 erastin results in decreased expression of GPX4 protein
erastin promotes the reaction [Silicon Dioxide results in decreased expression of GPX4 protein]
astaxanthine inhibits the reaction [erastin results in decreased expression of GPX4 protein]; ferrostatin-1 inhibits the reaction [erastin results in decreased expression of GPX4 protein]; gap 27 peptide inhibits the reaction [erastin results in decreased expression of GPX4 protein]; GJA1 protein affects the reaction [erastin results in decreased expression of GPX4 protein]; SESN1 protein inhibits the reaction [erastin results in decreased expression of GPX4 protein]		 CTD PMID:31323261 PMID:32937103 PMID:34785303 PMID:37075931 PMID:37648051 NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta multiple interactions
increases expression		 ISO cordycepin inhibits the reaction [erastin results in increased expression of GSK3B protein] CTD PMID:38014886 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G Hmga2 high mobility group AT-hook 2 multiple interactions
increases expression		 ISO Doxycycline promotes the reaction [erastin results in increased expression of HMGA2 mRNA] CTD PMID:38115220 NCBI chr 7:55,877,145...55,998,813
Ensembl chr 7:55,880,112...55,994,784 		JBrowse link
G Hmox1 heme oxygenase 1 increases expression
increases response to substance
multiple interactions		 ISO erastin results in increased expression of HMOX1 protein
HMOX1 protein results in increased susceptibility to erastin
Doxycycline promotes the reaction [erastin results in increased expression of HMOX1 mRNA]
erastin results in increased expression of HMOX1 mRNA; erastin results in increased expression of HMOX1 protein		 CTD PMID:30817950 PMID:38115220 PMID:38641223 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hras HRas proto-oncogene, GTPase increases response to substance ISO HRAS protein modified form results in increased susceptibility to erastin CTD PMID:17568748 NCBI chr 1:196,290,127...196,299,823
Ensembl chr 1:196,296,263...196,300,615 		JBrowse link
G Hspa5 heat shock protein family A (Hsp70) member 5 increases expression
multiple interactions		 ISO erastin results in increased expression of HSPA5 protein
erastin promotes the reaction [Silicon Dioxide results in increased expression of HSPA5 protein]		 CTD PMID:37075931 NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891 		JBrowse link
G Hspb1 heat shock protein family B (small) member 1 decreases phosphorylation EXP erastin results in decreased phosphorylation of HSPB1 protein CTD PMID:32937103 NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743 		JBrowse link
G Krt5 keratin 5 multiple interactions
increases expression		 ISO Doxycycline promotes the reaction [erastin results in increased expression of KRT5 mRNA] CTD PMID:38115220 NCBI chr 7:132,846,132...132,851,861
Ensembl chr 7:132,846,136...132,851,850 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta increases expression
multiple interactions		 EXP erastin results in increased expression of MAP1LC3B protein modified form
3-methyladenine inhibits the reaction [erastin results in increased expression of MAP1LC3B protein modified form]; Chloroquine promotes the reaction [erastin results in increased expression of MAP1LC3B protein modified form]		 CTD PMID:32937103 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 increases phosphorylation
multiple interactions		 ISO erastin results in increased phosphorylation of MAPK1 protein
GW 506033X inhibits the reaction [erastin results in increased phosphorylation of MAPK1 protein]		 CTD PMID:30817950 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation		 ISO GW 506033X inhibits the reaction [erastin results in increased phosphorylation of MAPK3 protein] CTD PMID:30817950 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases phosphorylation
multiple interactions		 ISO erastin results in increased phosphorylation of MAPK8 protein
GW 506033X inhibits the reaction [erastin results in increased phosphorylation of MAPK8 protein]		 CTD PMID:30817950 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Mb myoglobin multiple interactions
increases response to substance
increases expression		 ISO Doxycycline promotes the reaction [erastin results in increased expression of MB mRNA]
MB protein results in increased susceptibility to erastin		 CTD PMID:38115220 NCBI chr 7:108,759,903...108,767,134
Ensembl chr 7:108,759,904...108,767,383 		JBrowse link
G Mki67 marker of proliferation Ki-67 decreases expression
multiple interactions		 ISO erastin results in decreased expression of MKI67 protein
Butyric Acid promotes the reaction [erastin results in decreased expression of MKI67 protein]
BGN mRNA alternative form inhibits the reaction [erastin results in decreased expression of MKI67 protein]		 CTD PMID:35234341 PMID:37341073 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762 		JBrowse link
G Msh2 mutS homolog 2 increases expression ISO erastin results in increased expression of MSH2 mRNA alternative form CTD PMID:35234341 NCBI chr 6:6,813,793...6,872,960
Ensembl chr 6:6,813,795...6,872,938 		JBrowse link
G Ncoa4 nuclear receptor coactivator 4 decreases expression
multiple interactions		 EXP
ISO		 erastin results in decreased expression of NCOA4 protein
[PRKD2 protein affects the susceptibility to erastin] which affects the expression of NCOA4 protein; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of NCOA4 protein]; Chloroquine affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of NCOA4 protein]
3-methyladenine inhibits the reaction [erastin results in decreased expression of NCOA4 protein]; Chloroquine inhibits the reaction [erastin results in decreased expression of NCOA4 protein]		 CTD PMID:32937103 PMID:37951334 NCBI chr16:7,389,222...7,409,564
Ensembl chr16:7,366,542...7,409,641
Ensembl chr16:7,366,542...7,409,641 		JBrowse link
G Nfatc2 nuclear factor of activated T-cells 2 multiple interactions ISO erastin promotes the reaction [Silicon Dioxide results in increased expression of NFATC2 protein] CTD PMID:37075931 NCBI chr 3:157,195,970...157,328,640
Ensembl chr 3:157,198,872...157,328,325 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions
decreases expression
increases expression		 ISO
EXP		 NFE2L2 protein affects the reaction [erastin results in increased expression of SESN2 protein]
erastin results in decreased expression of NFE2L2 protein
cordycepin inhibits the reaction [erastin results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [erastin results in increased expression of SESN2 protein]
erastin results in increased expression of NFE2L2 protein
NFE2L2 protein promotes the reaction [erastin results in increased expression of FTH1 protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLC protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of GCLM protein]; NFE2L2 protein promotes the reaction [erastin results in increased expression of SLC7A11 mRNA]		 CTD PMID:31323261 PMID:32937103 PMID:38014886 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
multiple interactions		 ISO erastin results in increased cleavage of PARP1 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide promotes the reaction [erastin results in increased cleavage of PARP1 protein]		 CTD PMID:38641223 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Prkd2 protein kinase D2 affects response to substance
multiple interactions		 ISO PRKD2 protein affects the susceptibility to erastin
[PRKD2 protein affects the susceptibility to [erastin co-treated with bafilomycin A1]] which affects the abundance of Malondialdehyde; [PRKD2 protein affects the susceptibility to erastin] which affects the abundance of Malondialdehyde; [PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTH1 protein; [PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTL protein; [PRKD2 protein affects the susceptibility to erastin] which affects the expression of NCOA4 protein; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTH1 protein]; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTL protein]; bafilomycin A1 affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of NCOA4 protein]; Chloroquine affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTH1 protein]; Chloroquine affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of FTL protein]; Chloroquine affects the reaction [[PRKD2 protein affects the susceptibility to erastin] which affects the expression of NCOA4 protein]; PRKD2 protein affects the susceptibility to [erastin co-treated with bafilomycin A1]		 CTD PMID:37951334 NCBI chr 1:77,513,625...77,542,386
Ensembl chr 1:77,513,986...77,542,376 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 increases expression
multiple interactions
decreases expression		 EXP
ISO		 erastin results in increased expression of PTGS2 mRNA; erastin results in increased expression of PTGS2 protein
Quercetin inhibits the reaction [erastin results in increased expression of PTGS2 protein]; Quercetin promotes the reaction [erastin results in decreased expression of PTGS2 protein]
Vitamin E inhibits the reaction [erastin analog results in increased expression of PTGS2 mRNA]
erastin analog results in increased expression of PTGS2 mRNA; erastin results in increased expression of PTGS2 mRNA		 CTD PMID:24439385 PMID:32937103 PMID:37230155 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Rnasel ribonuclease L increases expression
multiple interactions		 ISO erastin results in increased expression of RNASEL mRNA
Doxycycline promotes the reaction [erastin results in increased expression of RNASEL mRNA]		 CTD PMID:38115220 NCBI chr13:65,894,990...65,910,354
Ensembl chr13:65,901,459...65,908,704 		JBrowse link
G Rnf38 ring finger protein 38 multiple interactions ISO [Doxycycline co-treated with erastin] results in increased expression of RNF38 mRNA CTD PMID:38115220 NCBI chr 5:58,358,771...58,467,424
Ensembl chr 5:58,361,976...58,467,446 		JBrowse link
G Sc5d sterol-C5-desaturase increases expression ISO erastin results in increased expression of SC5D mRNA alternative form CTD PMID:35234341 NCBI chr 8:42,629,649...42,641,257
Ensembl chr 8:42,632,672...42,641,273 		JBrowse link
G Sesn1 sestrin 1 multiple interactions ISO SESN1 protein inhibits the reaction [erastin results in decreased expression of GPX4 protein] CTD PMID:31323261 NCBI chr20:45,294,876...45,387,698
Ensembl chr20:45,294,871...45,387,697 		JBrowse link
G Sesn2 sestrin 2 multiple interactions
increases expression		 ISO NFE2L2 protein affects the reaction [erastin results in increased expression of SESN2 protein]
Acetylcysteine inhibits the reaction [erastin results in increased expression of SESN2 protein]; Butylated Hydroxyanisole inhibits the reaction [erastin results in increased expression of SESN2 protein]; Dactinomycin inhibits the reaction [erastin results in increased expression of SESN2 mRNA]; Deferoxamine inhibits the reaction [erastin results in increased expression of SESN2 protein]; diphenyleneiodonium inhibits the reaction [erastin results in increased expression of SESN2 protein]; ferrostatin-1 inhibits the reaction [erastin results in increased expression of SESN2 protein]; NFE2L2 protein affects the reaction [erastin results in increased expression of SESN2 protein]
erastin results in increased expression of SESN2 mRNA; erastin results in increased expression of SESN2 protein		 CTD PMID:31323261 NCBI chr 5:144,702,287...144,721,241
Ensembl chr 5:144,701,530...144,721,260 		JBrowse link
G Slc11a2 solute carrier family 11 member 2 increases expression EXP erastin results in increased expression of SLC11A2 protein CTD PMID:32937103 NCBI chr 7:131,503,076...131,540,246
Ensembl chr 7:131,503,081...131,540,145 		JBrowse link
G Slc40a1 solute carrier family 40 member 1 decreases expression
increases expression		 EXP
ISO		 erastin results in decreased expression of SLC40A1 protein
erastin results in increased expression of SLC40A1 protein		 CTD PMID:31323261 PMID:32937103 NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481 		JBrowse link
G Slc7a11 solute carrier family 7 member 11 increases expression
multiple interactions
decreases expression		 EXP
ISO		 erastin results in increased expression of SLC7A11 mRNA
erastin results in increased expression of SLC7A11 mRNA; erastin results in increased expression of SLC7A11 protein
erastin promotes the reaction [Silicon Dioxide results in decreased expression of SLC7A11 protein]
erastin results in decreased expression of SLC7A11 protein
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [[indol-3-yl pyruvic acid co-treated with erastin] results in increased expression of SLC7A11 protein]; 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide inhibits the reaction [erastin results in increased expression of SLC7A11 protein]; [indol-3-yl pyruvic acid co-treated with erastin] results in increased expression of SLC7A11 protein; AHR protein affects the reaction [[indol-3-yl pyruvic acid co-treated with erastin] results in increased expression of SLC7A11 protein]; AHR protein affects the reaction [erastin results in increased expression of SLC7A11 mRNA]; AHR protein affects the reaction [erastin results in increased expression of SLC7A11 protein]; gap 27 peptide inhibits the reaction [erastin results in decreased expression of SLC7A11 protein]; GJA1 protein affects the reaction [erastin results in decreased expression of SLC7A11 protein]
NFE2L2 protein promotes the reaction [erastin results in increased expression of SLC7A11 mRNA]		 CTD PMID:32937103 PMID:34785303 PMID:37075931 PMID:38641223 NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536 		JBrowse link
G Slpi secretory leukocyte peptidase inhibitor multiple interactions
increases expression		 ISO Doxycycline promotes the reaction [erastin results in increased expression of SLPI mRNA] CTD PMID:38115220 NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453 		JBrowse link
G Taf1a TATA-box binding protein associated factor, RNA polymerase I subunit A decreases expression ISO erastin results in decreased expression of TAF1A mRNA alternative form CTD PMID:35234341 NCBI chr13:95,012,160...95,048,131
Ensembl chr13:95,029,225...95,048,087 		JBrowse link
G Tf transferrin increases expression
multiple interactions		 EXP erastin results in increased expression of TF mRNA; erastin results in increased expression of TF protein
Quercetin inhibits the reaction [erastin results in increased expression of TF mRNA]; Quercetin inhibits the reaction [erastin results in increased expression of TF protein]		 CTD PMID:32937103 PMID:37230155 NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511 		JBrowse link
G Tfrc transferrin receptor increases expression EXP
ISO		 erastin results in increased expression of TFRC protein CTD PMID:31323261 PMID:32937103 NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257 		JBrowse link
G Timp1 TIMP metallopeptidase inhibitor 1 decreases expression ISO erastin results in decreased expression of TIMP1 mRNA alternative form CTD PMID:35234341 NCBI chr  X:1,212,969...1,217,714
Ensembl chr  X:1,212,972...1,217,664 		JBrowse link
G Vdac2 voltage-dependent anion channel 2 decreases expression
affects binding
increases degradation		 ISO
EXP		 erastin results in decreased expression of VDAC2 protein
erastin analog binds to VDAC2 protein
erastin results in increased degradation of VDAC2 protein		 CTD PMID:17568748 PMID:32937103 NCBI chr15:2,462,877...2,476,802
Ensembl chr15:2,463,056...2,476,553 		JBrowse link
G Vdac3 voltage-dependent anion channel 3 increases degradation
decreases expression
affects response to substance		 EXP
ISO		 erastin results in increased degradation of VDAC3 protein
erastin results in decreased expression of VDAC3 protein
VDAC3 protein affects the susceptibility to erastin		 CTD PMID:17568748 PMID:32937103 NCBI chr16:69,434,982...69,451,473
Ensembl chr16:69,435,005...69,451,471 		JBrowse link
G Wdr41 WD repeat domain 41 decreases expression ISO erastin results in decreased expression of WDR41 mRNA alternative form CTD PMID:35234341 NCBI chr 2:26,222,797...26,273,849
Ensembl chr 2:26,224,495...26,273,836 		JBrowse link
G Wnt5a Wnt family member 5A multiple interactions
increases expression		 ISO erastin promotes the reaction [Silicon Dioxide results in increased expression of WNT5A protein]
erastin results in increased expression of WNT5A protein		 CTD PMID:37075931 NCBI chr16:3,697,032...3,718,230
Ensembl chr16:3,697,032...3,718,234 		JBrowse link
erlotinib hydrochloride term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [ABCG2 gene mutant form results in decreased susceptibility to Mitoxantrone]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 protein results in decreased susceptibility to Mitoxantrone]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 protein results in increased export of Methotrexate]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 results in increased export of Methotrexate] CTD PMID:18829547 PMID:19232821 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409 		JBrowse link
G Acaca acetyl-CoA carboxylase alpha increases phosphorylation ISO Erlotinib Hydrochloride results in increased phosphorylation of ACACA protein CTD PMID:23707608 NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457 		JBrowse link
G Adgre1 adhesion G protein-coupled receptor E1 multiple interactions ISO [Interleukin 1 Receptor Antagonist Protein co-treated with Erlotinib Hydrochloride] results in decreased expression of ADGRE1 protein CTD PMID:27738319 NCBI chr 9:2,242,476...2,398,000
Ensembl chr 9:2,242,474...2,398,000 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation
multiple interactions		 ISO Erlotinib Hydrochloride results in decreased phosphorylation of AKT1 protein
Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of AKT1 protein]		 CTD PMID:21195724 PMID:30623574 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 multiple interactions ISO [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in increased expression of APAF1 mRNA CTD PMID:29274334 NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540 		JBrowse link
G Areg amphiregulin affects response to substance ISO AREG protein affects the susceptibility to Erlotinib Hydrochloride CTD PMID:18980991 NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535 		JBrowse link
G Arf1 ARF GTPase 1 decreases response to substance ISO ARF1 mRNA results in decreased susceptibility to Erlotinib Hydrochloride CTD PMID:23125191 NCBI chr10:43,997,983...44,014,461
Ensembl chr10:43,997,986...44,014,434 		JBrowse link
G Atf4 activating transcription factor 4 increases expression EXP Erlotinib Hydrochloride results in increased expression of ATF4 protein CTD PMID:24768708 NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446 		JBrowse link
G Atg5 autophagy related 5 decreases response to substance
increases expression		 ISO ATG5 protein results in decreased susceptibility to Erlotinib Hydrochloride
Erlotinib Hydrochloride results in increased expression of ATG5 protein		 CTD PMID:21655094 PMID:23917044 NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209 		JBrowse link
G Atg7 autophagy related 7 increases expression ISO Erlotinib Hydrochloride results in increased expression of ATG7 protein CTD PMID:21655094 NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593 		JBrowse link
G Atm ATM serine/threonine kinase multiple interactions ISO Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of ATM mRNA] CTD PMID:29274334 NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437 		JBrowse link
G Atr ATR serine/threonine kinase multiple interactions
increases expression		 ISO Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of ATR mRNA]
Erlotinib Hydrochloride results in increased expression of ATR mRNA		 CTD PMID:29274334 NCBI chr 8:96,426,704...96,524,152
Ensembl chr 8:96,426,724...96,524,136 		JBrowse link
G Axl Axl receptor tyrosine kinase decreases response to substance
multiple interactions		 ISO AXL results in decreased susceptibility to Erlotinib Hydrochloride
[amuvatinib results in decreased activity of AXL protein] which results in increased susceptibility to Erlotinib Hydrochloride; [GSK 1363089 results in decreased activity of AXL protein] which results in increased susceptibility to Erlotinib Hydrochloride		 CTD PMID:22751098 NCBI chr 1:81,265,088...81,296,278
Ensembl chr 1:81,265,088...81,296,265 		JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions ISO Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of BAD mRNA] CTD PMID:29274334 NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of BAX mRNA] CTD PMID:29274334 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bbc3 Bcl-2 binding component 3 multiple interactions
increases expression		 ISO [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in increased expression of BBC3 mRNA; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of BBC3 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of BBC3 protein] CTD PMID:25895606 PMID:29274334 NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509 		JBrowse link
G Bcl2 BCL2, apoptosis regulator increases expression
multiple interactions		 ISO Erlotinib Hydrochloride results in increased expression of BCL2 mRNA; Erlotinib Hydrochloride results in increased expression of BCL2 protein
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of BCL2 mRNA; [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein]		 CTD PMID:23894143 PMID:29274334 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bcl2l11 Bcl2-like 11 multiple interactions
increases expression		 ISO Harmine promotes the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L11 protein] CTD PMID:30171258 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068 		JBrowse link
G Bcl2l2 Bcl2-like 2 increases expression
multiple interactions		 ISO Erlotinib Hydrochloride results in increased expression of BCL2L2 mRNA; Erlotinib Hydrochloride results in increased expression of BCL2L2 protein
[Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein]		 CTD PMID:23894143 NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624 		JBrowse link
G Becn1 beclin 1 decreases response to substance ISO BECN1 protein results in decreased susceptibility to Erlotinib Hydrochloride CTD PMID:23917044 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions
decreases expression		 ISO [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of BIRC5 mRNA; Erlotinib Hydrochloride inhibits the reaction [Betulinic Acid results in decreased expression of BIRC5 protein]; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in decreased expression of BIRC5 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased expression of BIRC5 protein] CTD PMID:25895606 PMID:29274334 PMID:30136359 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380 		JBrowse link
G Bnip3 BCL2 interacting protein 3 multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein] CTD PMID:25981168 NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359 		JBrowse link
G Braf B-Raf proto-oncogene, serine/threonine kinase decreases activity ISO Erlotinib Hydrochloride results in decreased activity of BRAF protein mutant form CTD PMID:29407956 NCBI chr 4:68,375,484...68,510,652
Ensembl chr 4:68,384,649...68,510,463 		JBrowse link
G Brca1 BRCA1, DNA repair associated multiple interactions ISO [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased phosphorylation of BRCA1 protein CTD PMID:23548265 NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304 		JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
increases activity		 ISO Erlotinib Hydrochloride results in increased cleavage of CASP3 protein
[TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of CASP3 protein
Erlotinib Hydrochloride results in increased activity of CASP3 protein
Erlotinib Hydrochloride promotes the reaction [resveratrol results in increased activity of CASP3 protein]; resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased activity of CASP3 protein]		 CTD PMID:23125191 PMID:25895606 PMID:30171258 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of CCL2 mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of CCL2 mRNA CTD PMID:27738319 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of CCNB1 mRNA CTD PMID:29274334 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein] CTD PMID:19168569 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Cd69 Cd69 molecule decreases expression ISO Erlotinib Hydrochloride results in decreased expression of CD69 protein CTD PMID:21195724 NCBI chr 4:162,725,446...162,733,364
Ensembl chr 4:162,725,446...162,733,542 		JBrowse link
G Cdh1 cadherin 1 multiple interactions
decreases expression		 ISO
EXP		 Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in increased degradation of CDH1 protein]; Erlotinib Hydrochloride results in decreased glycosylation of and results in increased degradation of CDH1 protein
Erlotinib Hydrochloride results in decreased expression of CDH1 mRNA; Erlotinib Hydrochloride results in decreased expression of CDH1 protein
DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of CDH1 protein]		 CTD PMID:22223758 PMID:24768708 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775 		JBrowse link
G Cdk4 cyclin-dependent kinase 4 decreases phosphorylation ISO Erlotinib Hydrochloride results in decreased phosphorylation of CDK4 protein CTD PMID:21195724 NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403 		JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions
decreases expression		 ISO Betulinic Acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of CDK6 protein] CTD PMID:30136359 NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression
multiple interactions		 ISO Erlotinib Hydrochloride results in increased expression of CDKN1A mRNA
Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of CDKN1A mRNA]		 CTD PMID:29274334 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Chfr checkpoint with forkhead and ring finger domains multiple interactions ISO CHFR protein affects the susceptibility to [Cisplatin co-treated with Erlotinib Hydrochloride] CTD PMID:20705357 NCBI chr12:46,504,497...46,538,104
Ensembl chr12:46,504,497...46,538,014 		JBrowse link
G Chrdl2 chordin-like 2 multiple interactions ISO [Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of CHRDL2 protein CTD PMID:24979617 NCBI chr 1:154,343,201...154,370,651
Ensembl chr 1:154,343,201...154,370,640 		JBrowse link
G Csf3 colony stimulating factor 3 increases secretion ISO Erlotinib Hydrochloride results in increased secretion of CSF3 protein CTD PMID:27738319 NCBI chr10:83,660,787...83,664,569
Ensembl chr10:83,661,207...83,663,603 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions
affects phosphorylation
decreases expression		 ISO [Betulinic Acid co-treated with Erlotinib Hydrochloride] results in decreased expression of CTNNB1 protein
Erlotinib Hydrochloride affects the phosphorylation of CTNNB1 protein
Erlotinib Hydrochloride results in decreased expression of CTNNB1 protein		 CTD PMID:30136359 PMID:34463000 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111 		JBrowse link
G Cxcl11 C-X-C motif chemokine ligand 11 multiple interactions ISO [Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of CXCL11 protein CTD PMID:24979617 NCBI chr14:15,689,432...15,692,207
Ensembl chr14:15,689,424...15,692,271 		JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 decreases activity ISO Erlotinib Hydrochloride results in decreased activity of CYP19A1 protein CTD PMID:26141389 NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 decreases activity ISO Erlotinib Hydrochloride results in decreased activity of CYP1A1 protein CTD PMID:33814510 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 decreases activity ISO Erlotinib Hydrochloride results in decreased activity of CYP1B1 protein CTD PMID:33814510 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917 		JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 increases expression ISO Erlotinib Hydrochloride results in increased expression of CYP2B6 mRNA CTD PMID:30364229 NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 decreases activity
increases expression		 ISO Erlotinib Hydrochloride results in decreased activity of CYP3A4 protein
Erlotinib Hydrochloride results in increased expression of CYP3A4 mRNA		 CTD PMID:18839173 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp51 cytochrome P450, family 51 increases response to substance ISO CYP51A1 mRNA results in increased susceptibility to Erlotinib Hydrochloride CTD PMID:23125191 NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
Ensembl chr 6:30,036,865...30,055,410 		JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression
multiple interactions		 ISO
EXP		 Erlotinib Hydrochloride results in increased expression of DDIT3 protein
DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of CDH1 protein]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased expression of IL6 mRNA]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein]		 CTD PMID:24768708 NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201 		JBrowse link
G Dennd6b DENN domain containing 6B decreases expression ISO Erlotinib Hydrochloride results in decreased expression of DENND6B mRNA CTD PMID:27720938 NCBI chr 7:120,261,679...120,273,667
Ensembl chr 7:120,261,679...120,273,494 		JBrowse link
G Dusp1 dual specificity phosphatase 1 multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of DUSP1 mRNA CTD PMID:27738319 NCBI chr10:16,680,478...16,683,275 JBrowse link
G Egf epidermal growth factor multiple interactions ISO
EXP		 Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Cisplatin]]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in decreased susceptibility to Crizotinib]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased activity of ELK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein]; Erlotinib Hydrochloride promotes the reaction [EGF protein binds to EGFR protein]
Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]		 CTD PMID:21613822 PMID:21787763 PMID:22553343 PMID:25625231 PMID:27427493 More... NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064 		JBrowse link
G Egfr epidermal growth factor receptor affects response to substance
decreases expression
decreases phosphorylation
decreases activity
multiple interactions
decreases response to substance		 ISO EGFR protein affects the susceptibility to Erlotinib Hydrochloride; EGFR protein mutant form affects the susceptibility to Erlotinib Hydrochloride
Erlotinib Hydrochloride results in decreased expression of EGFR protein modified form
Erlotinib Hydrochloride results in decreased phosphorylation of EGFR protein
Erlotinib Hydrochloride results in decreased activity of EGFR protein
[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD50 protein; [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD51 protein; [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased phosphorylation of BRCA1 protein; EGFR gene mutant form results in increased susceptibility to [Gemcitabine co-treated with Cisplatin co-treated with Erlotinib Hydrochloride]; Erlotinib Hydrochloride inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein]; Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein]; Erlotinib Hydrochloride promotes the reaction [EGF protein binds to EGFR protein]; Erlotinib Hydrochloride results in decreased activity of and results in decreased phosphorylation of EGFR protein; Erlotinib Hydrochloride results in decreased glycosylation of and results in decreased expression of EGFR protein
EGFR protein mutant form results in decreased susceptibility to Erlotinib Hydrochloride		 CTD PMID:12907618 PMID:16407879 PMID:16891461 PMID:19168569 PMID:21080748 More... NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha increases expression EXP Erlotinib Hydrochloride results in increased expression of EIF2S1 protein modified form CTD PMID:24768708 NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225 		JBrowse link
G Elk1 ETS transcription factor ELK1 multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased activity of ELK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein] CTD PMID:25625231 PMID:30364229 NCBI chr  X:1,138,826...1,155,713
Ensembl chr  X:1,139,756...1,155,713 		JBrowse link
G Erbb3 erb-b2 receptor tyrosine kinase 3 decreases response to substance ISO ERBB3 mRNA results in decreased susceptibility to Erlotinib Hydrochloride CTD PMID:23125191 NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525 		JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO Erlotinib Hydrochloride affects the expression of and affects the phosphorylation of ESR1 protein CTD PMID:34463000 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002 		JBrowse link
G Foxg1 forkhead box G1 multiple interactions
decreases expression		 ISO Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein]
Erlotinib Hydrochloride results in decreased expression of FOXG1 protein		 CTD PMID:26455392 NCBI chr 6:66,674,797...66,677,611
Ensembl chr 6:66,666,587...66,678,607 		JBrowse link
G Foxo3 forkhead box O3 decreases phosphorylation ISO Erlotinib Hydrochloride results in decreased phosphorylation of FOXO3 protein CTD PMID:23099361 NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561 		JBrowse link
G Gdf15 growth differentiation factor 15 multiple interactions ISO [Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of GDF15 protein CTD PMID:24979617 NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055 		JBrowse link
G Gmpr guanosine monophosphate reductase decreases expression ISO Erlotinib Hydrochloride results in decreased expression of GMPR mRNA CTD PMID:27720938 NCBI chr17:19,151,820...19,189,626
Ensembl chr17:19,151,815...19,189,621 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta decreases expression ISO Erlotinib Hydrochloride results in decreased expression of GSK3B protein modified form CTD PMID:30136359 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G H2ax H2A.X variant histone multiple interactions
increases expression		 ISO Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of H2AX protein modified form]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of H2AX protein modified form] CTD PMID:25895606 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239 		JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [HBEGF protein results in decreased susceptibility to crizotinib] CTD PMID:22553343 NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441 		JBrowse link
G Ifitm3 interferon induced transmembrane protein 3 decreases expression ISO Erlotinib Hydrochloride results in decreased expression of IFITM3 mRNA CTD PMID:27720938 NCBI chr 1:196,111,026...196,112,135
Ensembl chr 1:196,111,043...196,112,203 		JBrowse link
G Ifng interferon gamma decreases secretion ISO Erlotinib Hydrochloride results in decreased secretion of IFNG protein CTD PMID:21195724 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375 		JBrowse link
G Il17f interleukin 17F increases expression ISO
EXP		 Erlotinib Hydrochloride results in increased expression of IL17F mRNA CTD PMID:24768708 NCBI chr 9:23,190,094...23,201,482
Ensembl chr 9:23,190,100...23,201,482 		JBrowse link
G Il1a interleukin 1 alpha multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of IL1A mRNA CTD PMID:27738319 NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases secretion		 ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of IL1B mRNA
Erlotinib Hydrochloride results in increased secretion of IL1B protein		 CTD PMID:27738319 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Il1r1 interleukin 1 receptor type 1 multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of IL1R1 mRNA CTD PMID:27738319 NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937 		JBrowse link
G Il1r2 interleukin 1 receptor type 2 multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of IL1R2 mRNA CTD PMID:27738319 NCBI chr 9:42,384,280...42,424,726
Ensembl chr 9:42,384,433...42,424,725 		JBrowse link
G Il1rap interleukin 1 receptor accessory protein multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of IL1RAP mRNA CTD PMID:27738319 NCBI chr11:74,062,999...74,199,530
Ensembl chr11:74,070,304...74,199,530 		JBrowse link
G Il1rn interleukin 1 receptor antagonist multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of IL1RN mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of IL1RN mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased secretion of IL1RN protein CTD PMID:27738319 NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445 		JBrowse link
G Il2 interleukin 2 decreases secretion ISO Erlotinib Hydrochloride results in decreased secretion of IL2 protein CTD PMID:21195724 NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566 		JBrowse link
G Il25 interleukin 25 increases expression ISO
EXP		 Erlotinib Hydrochloride results in increased expression of IL25 mRNA CTD PMID:24768708 NCBI chr15:28,408,766...28,412,157
Ensembl chr15:28,408,842...28,411,893 		JBrowse link
G Il2ra interleukin 2 receptor subunit alpha decreases expression ISO Erlotinib Hydrochloride results in decreased expression of IL2RA protein CTD PMID:21195724 NCBI chr17:66,849,974...66,898,665
Ensembl chr17:66,849,974...66,898,697 		JBrowse link
G Il6 interleukin 6 increases expression
increases secretion
multiple interactions		 ISO
EXP		 Erlotinib Hydrochloride results in increased expression of IL6 mRNA
Erlotinib Hydrochloride results in increased secretion of IL6 protein
Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased expression of IL6 mRNA]; Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased secretion of IL6 protein]; Interleukin 1 Receptor Antagonist Protein inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein]
DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased expression of IL6 mRNA]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein]		 CTD PMID:24768708 PMID:27738319 PMID:30623574 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Irak1 interleukin-1 receptor-associated kinase 1 multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of IRAK1 mRNA CTD PMID:27738319 NCBI chr  X:151,768,621...151,778,521
Ensembl chr  X:151,768,777...151,778,521 		JBrowse link
G Itgb1 integrin subunit beta 1 decreases expression EXP Erlotinib Hydrochloride results in decreased expression of ITGB1 mRNA CTD PMID:24768708 NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195 		JBrowse link
G Jak2 Janus kinase 2 decreases phosphorylation ISO Erlotinib Hydrochloride results in decreased phosphorylation of JAK2 protein CTD PMID:23894143 NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189 		JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 affects activity
decreases activity		 ISO Erlotinib Hydrochloride affects the activity of KCNH2 protein
Erlotinib Hydrochloride results in decreased activity of KCNH2 protein		 CTD PMID:23707608 PMID:35680041 NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008 		JBrowse link
G Kitlg KIT ligand multiple interactions ISO [Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of KITLG protein CTD PMID:24979617 NCBI chr 7:34,896,075...34,977,215
Ensembl chr 7:34,896,053...34,977,214 		JBrowse link
G Kras KRAS proto-oncogene, GTPase increases response to substance ISO KRAS protein results in increased susceptibility to Erlotinib Hydrochloride CTD PMID:20705357 NCBI chr 4:178,185,418...178,218,484 JBrowse link
G Ldha lactate dehydrogenase A increases secretion ISO Erlotinib Hydrochloride results in increased secretion of LDHA protein CTD PMID:37660997 NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO Erlotinib Hydrochloride promotes the reaction [Betulinic Acid results in increased expression of MAP1LC3B protein modified form] CTD PMID:30136359 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation
multiple interactions		 ISO
EXP		 Erlotinib Hydrochloride results in decreased phosphorylation of MAPK1 protein
Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of MAPK1 protein]
Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]
Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK1 protein]; Erlotinib Hydrochloride inhibits the reaction [carvedilol results in increased phosphorylation of MAPK1 protein]		 CTD PMID:18787115 PMID:18980991 PMID:21195724 PMID:27427493 PMID:28101945 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation
multiple interactions		 ISO
EXP		 Erlotinib Hydrochloride results in decreased phosphorylation of MAPK3 protein
Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of MAPK3 protein]
Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]
Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK3 protein]; Erlotinib Hydrochloride inhibits the reaction [carvedilol results in increased phosphorylation of MAPK3 protein]		 CTD PMID:18787115 PMID:18980991 PMID:21195724 PMID:27427493 PMID:28101945 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member decreases expression
multiple interactions		 ISO Erlotinib Hydrochloride results in decreased expression of MCL1 protein
resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased expression of MCL1 protein]		 CTD PMID:25895606 NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303 		JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions
decreases phosphorylation		 ISO [Erlotinib Hydrochloride co-treated with Dasatinib] results in decreased phosphorylation of MET protein
Erlotinib Hydrochloride results in decreased phosphorylation of MET protein		 CTD PMID:21106725 PMID:23894143 NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876 		JBrowse link
G Micb MHC class I polypeptide-related sequence B increases expression ISO Erlotinib Hydrochloride results in increased expression of MICB protein CTD PMID:21951556 NCBI chr 1:78,495,779...78,513,030
Ensembl chr 1:78,495,779...78,512,827 		JBrowse link
G Mmp14 matrix metallopeptidase 14 multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [Acrolein results in increased expression of MMP14 mRNA] CTD PMID:19661247 NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864 		JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of MMP2 mRNA CTD PMID:29274334 NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of MMP9 mRNA CTD PMID:29274334 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Msmo1 methylsterol monooxygenase 1 decreases response to substance
multiple interactions		 ISO MSMO1 protein results in decreased susceptibility to Erlotinib Hydrochloride
MSMO1 protein inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form]		 CTD PMID:23125191 NCBI chr16:24,980,680...24,997,927
Ensembl chr16:24,980,697...24,998,016 		JBrowse link
G Mtor mechanistic target of rapamycin kinase decreases phosphorylation
multiple interactions		 ISO Erlotinib Hydrochloride results in decreased phosphorylation of MTOR protein
resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased phosphorylation of MTOR protein]		 CTD PMID:21655094 PMID:25895606 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311 		JBrowse link
G Muc5ac mucin 5AC, oligomeric mucus/gel-forming multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [Acrolein results in increased expression of MUC5AC mRNA] CTD PMID:18006877 PMID:19661247 NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor affects expression ISO Erlotinib Hydrochloride affects the expression of MYC protein CTD PMID:34463000 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630 		JBrowse link
G Myd88 MYD88, innate immune signal transduction adaptor multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of MYD88 mRNA CTD PMID:27738319 NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of NFKBIA mRNA CTD PMID:27738319 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Nol10 nucleolar protein 10 decreases expression ISO Erlotinib Hydrochloride results in decreased expression of NOL10 mRNA CTD PMID:27720938 NCBI chr 6:40,144,217...40,225,353
Ensembl chr 6:40,144,235...40,225,353 		JBrowse link
G Nox4 NADPH oxidase 4 multiple interactions
decreases response to substance
increases expression		 ISO Erlotinib Hydrochloride results in increased expression of and results in increased stability of NOX4 mRNA
NOX4 protein results in decreased susceptibility to Erlotinib Hydrochloride
Erlotinib Hydrochloride results in increased expression of NOX4 protein		 CTD PMID:23917044 NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406 		JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO Erlotinib Hydrochloride binds to and results in increased activity of NR1I2 protein CTD PMID:18839173 NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658 		JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 affects localization ISO Erlotinib Hydrochloride affects the localization of NR1I3 protein mutant form CTD PMID:30364229 NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906 		JBrowse link
G Nsdhl NAD(P) dependent steroid dehydrogenase-like decreases response to substance ISO NSDHL protein results in decreased susceptibility to Erlotinib Hydrochloride CTD PMID:23125191 NCBI chr  X:150,775,034...150,807,161
Ensembl chr  X:150,775,080...150,807,142 		JBrowse link
G Osm oncostatin M multiple interactions ISO [Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of OSM protein CTD PMID:24979617 NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
multiple interactions
increases expression		 ISO Erlotinib Hydrochloride results in increased cleavage of PARP1 protein
[TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of PARP1 protein; Harmine promotes the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of PARP1 protein modified form]; TWIST1 protein inhibits the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein]		 CTD PMID:23125191 PMID:25895606 PMID:30171258 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pik3ca phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [carvacrol results in increased phosphorylation of PIK3CA protein] CTD PMID:32535744 NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032 		JBrowse link
G Pml PML nuclear body scaffold increases expression
decreases response to substance
increases localization		 ISO Erlotinib Hydrochloride results in increased expression of PML protein
PML protein results in decreased susceptibility to Erlotinib Hydrochloride
Erlotinib Hydrochloride results in increased localization of PML protein		 CTD PMID:23440206 NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of PTGS2 mRNA CTD PMID:27738319 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Ptpn9 protein tyrosine phosphatase, non-receptor type 9 decreases expression
decreases response to substance		 ISO Erlotinib Hydrochloride results in decreased expression of PTPN9 protein
PTPN9 mutant form results in decreased susceptibility to Erlotinib Hydrochloride		 CTD PMID:23894143 NCBI chr 8:57,391,290...57,472,352
Ensembl chr 8:57,391,259...57,470,952 		JBrowse link
G Rad50 RAD50 double strand break repair protein multiple interactions ISO [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD50 protein CTD PMID:23548265 NCBI chr10:37,809,353...37,861,309
Ensembl chr10:37,808,726...37,861,396 		JBrowse link
G Rad51 RAD51 recombinase multiple interactions ISO [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD51 protein CTD PMID:23548265 NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035 		JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase decreases phosphorylation ISO Erlotinib Hydrochloride results in decreased phosphorylation of RAF1 protein CTD PMID:21195724 NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317 		JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases phosphorylation
multiple interactions
decreases expression		 ISO Erlotinib Hydrochloride results in decreased phosphorylation of RB1 protein
Betulinic Acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of RB1 protein modified form]; Erlotinib Hydrochloride promotes the reaction [Betulinic Acid results in decreased expression of RB1 protein modified form]		 CTD PMID:21195724 PMID:30136359 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [carvacrol results in increased phosphorylation of RELA protein]; Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased acetylation of RELA protein] CTD PMID:28101945 PMID:32535744 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation
decreases expression
multiple interactions		 ISO Erlotinib Hydrochloride results in decreased phosphorylation of RPS6 protein
Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form
MSMO1 protein inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form]		 CTD PMID:23125191 PMID:23440206 NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 decreases phosphorylation
multiple interactions		 ISO Erlotinib Hydrochloride results in decreased phosphorylation of RPS6KB1 protein
resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased phosphorylation of RPS6KB1 protein]		 CTD PMID:21655094 PMID:25895606 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908 		JBrowse link
G Selenbp1 selenium binding protein 1 decreases expression ISO Erlotinib Hydrochloride results in decreased expression of SELENBP1 mRNA CTD PMID:27720938 NCBI chr 2:182,494,004...182,504,594
Ensembl chr 2:182,493,978...182,504,594 		JBrowse link
G Siah2 siah E3 ubiquitin protein ligase 2 decreases expression ISO Erlotinib Hydrochloride results in decreased expression of SIAH2 mRNA CTD PMID:27720938 NCBI chr 2:142,913,924...142,931,752
Ensembl chr 2:142,914,003...142,931,950 		JBrowse link
G Snai1 snail family transcriptional repressor 1 multiple interactions ISO [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of SNAI1 mRNA CTD PMID:29274334 NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969 		JBrowse link
G Snai2 snail family transcriptional repressor 2 multiple interactions ISO [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of SNAI2 mRNA CTD PMID:29274334 NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200 		JBrowse link
G Socs3 suppressor of cytokine signaling 3 increases expression EXP Erlotinib Hydrochloride results in increased expression of SOCS3 mRNA CTD PMID:24768708 NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787 		JBrowse link
G Sox9 SRY-box transcription factor 9 multiple interactions
decreases expression		 ISO Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein]
Erlotinib Hydrochloride results in decreased expression of SOX9 protein		 CTD PMID:26455392 NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994 		JBrowse link
G Sqstm1 sequestosome 1 increases expression ISO Erlotinib Hydrochloride results in increased expression of SQSTM1 protein CTD PMID:30136359 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase decreases phosphorylation ISO Erlotinib Hydrochloride results in decreased phosphorylation of SRC protein CTD PMID:23894143 NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 increases phosphorylation
decreases expression
increases response to substance
decreases response to substance
multiple interactions		 ISO Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein
Erlotinib Hydrochloride results in decreased expression of STAT3 protein modified form
STAT3 mutant form results in increased susceptibility to Erlotinib Hydrochloride
STAT3 mRNA results in decreased susceptibility to Erlotinib Hydrochloride
[Betulinic Acid co-treated with Erlotinib Hydrochloride] results in decreased expression of STAT3 protein modified form; [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein]		 CTD PMID:23125191 PMID:23894143 PMID:30136359 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057 		JBrowse link
G Tent5c terminal nucleotidyltransferase 5C decreases expression ISO Erlotinib Hydrochloride results in decreased expression of TENT5C mRNA CTD PMID:27720938 NCBI chr 2:187,853,026...187,875,260
Ensembl chr 2:187,853,024...187,894,744 		JBrowse link
G Tfap2a transcription factor AP-2 alpha multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]] CTD PMID:21499124 PMID:21951556 NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507 		JBrowse link
G Tgfa transforming growth factor alpha multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [TGFA protein results in decreased susceptibility to crizotinib] CTD PMID:22553343 NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Cisplatin]]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Gemcitabine]] CTD PMID:21613822 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Tmed2 transmembrane p24 trafficking protein 2 decreases response to substance ISO TMED2 mRNA results in decreased susceptibility to Erlotinib Hydrochloride CTD PMID:23125191 NCBI chr12:32,052,542...32,061,628
Ensembl chr12:32,052,543...32,071,903 		JBrowse link
G Tnfsf8 TNF superfamily member 8 multiple interactions ISO [Gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of TNFSF8 protein CTD PMID:24979617 NCBI chr 5:77,250,942...77,277,364
Ensembl chr 5:77,251,373...77,277,421 		JBrowse link
G Tollip toll interacting protein multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of TOLLIP mRNA CTD PMID:27738319 NCBI chr 1:196,961,585...196,984,252
Ensembl chr 1:196,950,771...196,983,625 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases expression		 ISO Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of TP53 mRNA]; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of TP53 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of TP53 protein] CTD PMID:25895606 PMID:29274334 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Traf6 TNF receptor associated factor 6 multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of TRAF6 mRNA CTD PMID:27738319 NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507 		JBrowse link
G Twist1 twist family bHLH transcription factor 1 increases expression
decreases response to substance
multiple interactions		 ISO Erlotinib Hydrochloride results in increased expression of TWIST1 protein
TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride
[TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of PARP1 protein; TWIST1 protein inhibits the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein]
[TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of CASP3 protein		 CTD PMID:30171258 NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653 		JBrowse link
G Tyms thymidylate synthetase decreases expression
multiple interactions		 ISO Erlotinib Hydrochloride results in decreased expression of TYMS protein
Betulinic Acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of TYMS protein]; Erlotinib Hydrochloride promotes the reaction [Betulinic Acid results in decreased expression of TYMS protein]		 CTD PMID:30136359 NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536 		JBrowse link
G Ulbp1 UL16 binding protein 1 increases expression
multiple interactions		 ISO Erlotinib Hydrochloride results in increased expression of ULBP1 mRNA; Erlotinib Hydrochloride results in increased expression of ULBP1 protein
Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]]; Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride results in increased expression of ULBP1 mRNA]		 CTD PMID:21499124 PMID:21951556 NCBI chr 1:1,694,255...1,716,160 JBrowse link
G Xbp1 X-box binding protein 1 increases expression EXP Erlotinib Hydrochloride results in increased expression of XBP1 protein modified form CTD PMID:24768708 NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693 		JBrowse link
Febrifugine term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Dhcr24 24-dehydrocholesterol reductase decreases expression ISO febrifugine results in decreased expression of DHCR24 mRNA CTD PMID:38431229 NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137 		JBrowse link
G Dhcr7 7-dehydrocholesterol reductase decreases expression ISO febrifugine results in decreased expression of DHCR7 mRNA; febrifugine results in decreased expression of DHCR7 protein CTD PMID:38431229 NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055 		JBrowse link
G Ldlr low density lipoprotein receptor decreases expression ISO febrifugine results in decreased expression of LDLR mRNA CTD PMID:38431229 NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580 		JBrowse link
G Lss lanosterol synthase decreases expression ISO febrifugine results in decreased expression of LSS mRNA CTD PMID:38431229 NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762 		JBrowse link
G Mki67 marker of proliferation Ki-67 decreases expression ISO febrifugine results in decreased expression of MKI67 protein CTD PMID:38431229 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762 		JBrowse link
G Sqle squalene epoxidase decreases expression ISO febrifugine results in decreased expression of SQLE mRNA; febrifugine results in decreased expression of SQLE protein CTD PMID:38431229 NCBI chr 7:90,867,973...90,883,623
Ensembl chr 7:90,868,011...90,883,618 		JBrowse link
fenazaquin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Odc1 ornithine decarboxylase 1 increases activity ISO fenazaquin results in increased activity of ODC1 protein CTD PMID:9834970 NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440 		JBrowse link
G Park7 Parkinsonism associated deglycase increases response to substance ISO PARK7 mutant form results in increased susceptibility to fenazaquin CTD PMID:21219333 NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970 		JBrowse link
gefitinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO gefitinib results in decreased activity of ABCB11 protein CTD PMID:20829430 PMID:23956101 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO [[gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein] which results in decreased export of Doxorubicin; [gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein; gefitinib inhibits the reaction [ABCG2 protein results in decreased susceptibility to Doxorubicin] CTD PMID:17938326 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409 		JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions
decreases expression		 ISO [Gefitinib co-treated with CCL2 protein] results in increased expression of ACTA2 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of ACTA2 protein
Gefitinib results in decreased expression of ACTA2 protein		 CTD PMID:33248157 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554 		JBrowse link
G Adora1 adenosine A1 receptor decreases expression ISO gefitinib results in decreased expression of ADORA1 mRNA CTD PMID:16685379 NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
increases phosphorylation
decreases phosphorylation
decreases expression		 ISO
EXP		 Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Gefitinib results in decreased expression of and results in decreased phosphorylation of AKT1 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of AKT1 protein]; Methionine inhibits the reaction [Gefitinib results in increased phosphorylation of AKT1 protein]
Gefitinib results in decreased expression of AKT1 mRNA
Gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [Folic Acid results in increased phosphorylation of AKT1 protein]; Gefitinib promotes the reaction [Urethane results in increased phosphorylation of AKT1 protein]; Methionine inhibits the reaction [Gefitinib promotes the reaction [Urethane results in increased phosphorylation of AKT1 protein]]		 CTD PMID:17805209 PMID:19233551 PMID:23255615 PMID:23948867 PMID:24568969 More... NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Ar androgen receptor multiple interactions ISO Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]] CTD PMID:29383186 NCBI chr  X:63,104,771...63,273,934
Ensembl chr  X:63,104,771...63,273,925 		JBrowse link
G Areg amphiregulin affects response to substance
multiple interactions
decreases response to substance		 ISO AREG protein affects the susceptibility to gefitinib
Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [Irinotecan metabolite results in increased expression of AREG mRNA]; Gefitinib inhibits the reaction [Irinotecan results in increased expression of AREG mRNA]
AREG protein results in decreased susceptibility to gefitinib		 CTD PMID:15496427 PMID:15723263 PMID:16230376 PMID:18980991 PMID:21258428 NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535 		JBrowse link
G Atg5 autophagy related 5 increases expression ISO gefitinib results in increased expression of ATG5 protein CTD PMID:21655094 NCBI chr20:47,798,217...47,889,216
Ensembl chr20:47,798,290...47,889,209 		JBrowse link
G Atg7 autophagy related 7 increases expression ISO gefitinib results in increased expression of ATG7 protein CTD PMID:21655094 NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593 		JBrowse link
G Aurka aurora kinase A decreases response to substance
multiple interactions		 ISO AURKA results in decreased susceptibility to gefitinib
[AURKA results in increased degradation of NFKBIA protein] which results in decreased susceptibility to Gefitinib; [TP53 protein results in decreased expression of AURKA protein] which results in increased susceptibility to Gefitinib		 CTD PMID:21216229 NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390 		JBrowse link
G Aven apoptosis and caspase activation inhibitor affects response to substance ISO AVEN protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 3:99,299,009...99,431,635
Ensembl chr 3:99,298,930...99,431,634 		JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions ISO [cucurbitacin B co-treated with Gefitinib] results in increased expression of BAD mRNA CTD PMID:26183715 NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823 		JBrowse link
G Bak1 BCL2-antagonist/killer 1 multiple interactions ISO [cucurbitacin B co-treated with Gefitinib] results in increased expression of BAK1 mRNA; [cucurbitacin B co-treated with Gefitinib] results in increased expression of BAK1 protein CTD PMID:26183715 NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression
multiple interactions		 EXP
ISO		 Gefitinib results in increased expression of BAX mRNA; Gefitinib results in increased expression of BAX protein
[cucurbitacin B co-treated with Gefitinib] results in increased expression of BAX mRNA; [cucurbitacin B co-treated with Gefitinib] results in increased expression of BAX protein		 CTD PMID:26183715 PMID:32370496 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [cucurbitacin B co-treated with Gefitinib] results in decreased expression of BCL2 mRNA; [cucurbitacin B co-treated with Gefitinib] results in decreased expression of BCL2 protein CTD PMID:26183715 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO [cucurbitacin B co-treated with Gefitinib] results in decreased expression of BCL2L1 mRNA CTD PMID:26183715 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479 		JBrowse link
G Bcl2l11 Bcl2-like 11 increases response to substance
multiple interactions		 ISO BCL2L11 protein results in increased susceptibility to gefitinib
[cucurbitacin B co-treated with Gefitinib] results in increased expression of BCL2L11 mRNA		 CTD PMID:20237869 PMID:26183715 NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068 		JBrowse link
G Becn1 beclin 1 multiple interactions ISO [MIR578 affects the susceptibility to Gefitinib] which affects the expression of BECN1 protein; SOCS2 protein affects the reaction [[MIR578 affects the susceptibility to Gefitinib] which affects the expression of BECN1 protein] CTD PMID:37948135 NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 increases expression
decreases expression
multiple interactions		 ISO gefitinib results in increased expression of BIRC5 protein
Gefitinib results in decreased expression of BIRC5 protein
leptomycin B promotes the reaction [Gefitinib results in decreased expression of BIRC5 protein]; tyrphostin AG 1024 inhibits the reaction [Gefitinib results in increased expression of BIRC5 protein]		 CTD PMID:17473213 PMID:28942004 PMID:36807944 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380 		JBrowse link
G Bnip3 BCL2 interacting protein 3 multiple interactions ISO gefitinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein] CTD PMID:25981168 NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359 		JBrowse link
G Casp1 caspase 1 increases activity
multiple interactions		 ISO Gefitinib metabolite results in increased activity of CASP1 protein
N-acetyl-tyrosyl-valyl-alanyl-aspartyl chloromethyl ketone inhibits the reaction [Gefitinib metabolite results in increased activity of CASP1 protein]		 CTD PMID:33132241 NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383 		JBrowse link
G Casp3 caspase 3 increases expression
increases cleavage
multiple interactions		 EXP
ISO		 gefitinib results in increased expression of CASP3 mRNA; gefitinib results in increased expression of CASP3 protein
Gefitinib results in increased cleavage of CASP3 protein
Gefitinib results in increased expression of CASP3 protein modified form
[Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of CASP3 protein modified form]
[cucurbitacin B co-treated with Gefitinib] results in increased cleavage of CASP3 protein; EGFR gene mutant form promotes the reaction [Gefitinib results in increased cleavage of and results in increased activity of CASP3 protein]; Gefitinib results in increased cleavage of and results in increased activity of CASP3 protein		 CTD PMID:23523951 PMID:26183715 PMID:27084042 PMID:27639429 PMID:33248157 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp8 caspase 8 increases cleavage ISO Gefitinib results in increased cleavage of CASP8 protein CTD PMID:31168030 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Cav1 caveolin 1 increases expression ISO gefitinib results in increased expression of CAV1 mRNA; gefitinib results in increased expression of CAV1 protein CTD PMID:19288272 NCBI chr 4:45,640,624...45,673,708
Ensembl chr 4:45,634,918...45,673,705 		JBrowse link
G Ccl2 C-C motif chemokine ligand 2 increases secretion
increases expression
multiple interactions		 ISO Gefitinib results in increased secretion of CCL2 protein
Gefitinib results in increased expression of CCL2 mRNA
[Gefitinib co-treated with CCL2 protein] results in increased expression of ACTA2 protein; [Gefitinib co-treated with CCL2 protein] results in increased expression of COL1A1 protein; [Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of CASP3 protein modified form]; [Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of PARP1 protein modified form]; [Gefitinib results in increased secretion of CCL2 protein] which results in decreased expression of CDH1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of ACTA2 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of COL1A1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of FN1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of VIM protein; cucurbitacin B inhibits the reaction [Gefitinib results in increased expression of CCL2 mRNA]		 CTD PMID:33248157 NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226 		JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO Gefitinib results in decreased expression of and affects the localization of CCNB1 protein CTD PMID:33548356 NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172 		JBrowse link
G Ccnd1 cyclin D1 decreases expression
multiple interactions		 ISO Gefitinib results in decreased expression of CCND1 protein
[cucurbitacin B co-treated with Gefitinib] results in decreased expression of CCND1 mRNA; [cucurbitacin B co-treated with Gefitinib] results in decreased expression of CCND1 protein
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of CCND1 mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of CCND1 protein]		 CTD PMID:16740687 PMID:17513607 PMID:23948867 PMID:26183715 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccnd3 cyclin D3 decreases expression ISO gefitinib results in decreased expression of CCND3 protein CTD PMID:16740687 NCBI chr 9:13,394,161...13,400,341
Ensembl chr 9:13,394,169...13,489,371 		JBrowse link
G Cd14 CD14 molecule multiple interactions ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]]; [gefitinib promotes the reaction arsenic trioxide] which results in increased expression of CD14 mRNA; gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]; SB 203580 inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]] CTD PMID:20226526 NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261 		JBrowse link
G Cdh1 cadherin 1 multiple interactions
increases expression		 ISO [Gefitinib results in increased secretion of CCL2 protein] which results in decreased expression of CDH1 protein
Gefitinib results in increased expression of CDH1 protein		 CTD PMID:33248157 PMID:38517198 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775 		JBrowse link
G Cdk1 cyclin-dependent kinase 1 increases phosphorylation ISO Gefitinib results in increased phosphorylation of CDK1 protein CTD PMID:33548356 NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408 		JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions
decreases expression		 ISO Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of CDK6 protein] CTD PMID:30136359 NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression
multiple interactions
decreases expression		 ISO gefitinib results in increased expression of CDKN1A protein
leptomycin B inhibits the reaction [gefitinib results in decreased expression of CDKN1A protein]		 CTD PMID:17513607 PMID:28942004 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
increases expression
decreases expression		 ISO [cucurbitacin B co-treated with Gefitinib] results in increased expression of CDKN1B protein; Gefitinib promotes the reaction [[Zoledronic Acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased expression of CDKN1B protein]
Gefitinib results in increased expression of CDKN1B protein
gefitinib results in decreased expression of CDKN1B		 CTD PMID:14679152 PMID:16322342 PMID:16740687 PMID:17513607 PMID:26183715 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982 		JBrowse link
G Cdkn2b cyclin-dependent kinase inhibitor 2B increases expression ISO gefitinib results in increased expression of CDKN2B mRNA; gefitinib results in increased expression of CDKN2B protein CTD PMID:17513607 NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050 		JBrowse link
G Cert1 ceramide transporter 1 affects response to substance ISO CERT1 protein affects the susceptibility to Gefitinib CTD PMID:15496427 NCBI chr 2:27,882,546...27,987,090
Ensembl chr 2:27,882,555...27,987,074 		JBrowse link
G Cgrrf1 cell growth regulator with ring finger domain 1 increases expression ISO gefitinib results in increased expression of CGRRF1 mRNA CTD PMID:16685379 NCBI chr15:20,088,564...20,109,042
Ensembl chr15:20,088,571...20,109,037 		JBrowse link
G Cldn2 claudin 2 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of CLDN2 mRNA CTD PMID:20935109 NCBI chr  X:103,459,870...103,473,794
Ensembl chr  X:103,459,780...103,474,838 		JBrowse link
G Col1a1 collagen type I alpha 1 chain decreases expression
multiple interactions		 ISO Gefitinib results in decreased expression of COL1A1 protein
[Gefitinib co-treated with CCL2 protein] results in increased expression of COL1A1 protein; [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of COL1A1 protein		 CTD PMID:33248157 NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624 		JBrowse link
G Coro1c coronin 1C affects response to substance ISO CORO1C protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr12:42,713,024...42,785,179
Ensembl chr12:42,712,991...42,785,179 		JBrowse link
G Cycs cytochrome c, somatic affects localization ISO gefitinib affects the localization of CYCS protein CTD PMID:23523951 NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 increases response to substance
decreases activity
increases expression		 ISO
EXP		 CYP1A1 protein results in increased susceptibility to gefitinib
Gefitinib results in decreased activity of CYP1A1 protein
Gefitinib results in increased expression of CYP1A1 mRNA		 CTD PMID:28652202 PMID:32370496 PMID:33814510 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 decreases activity ISO Gefitinib results in decreased activity of CYP1B1 protein CTD PMID:33814510 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917 		JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 affects metabolic processing ISO CYP2D6 protein affects the metabolism of Gefitinib; CYP2D6 protein polymorphism affects the metabolism of Gefitinib CTD PMID:15788367 PMID:34936353 NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759 		JBrowse link
G Cyp2f4 cytochrome P450, family 2, subfamily f, polypeptide 4 decreases expression ISO gefitinib results in decreased expression of CYP2F1 mRNA CTD PMID:16685379 NCBI chr 1:82,416,107...82,429,897
Ensembl chr 1:82,416,130...82,429,896 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 affects metabolic processing ISO CYP3A4 protein affects the metabolism of Gefitinib CTD PMID:15788367 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 affects metabolic processing ISO CYP3A5 protein affects the metabolism of gefitinib CTD PMID:15788367 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422 		JBrowse link
G Dnajb1 DnaJ heat shock protein family (Hsp40) member B1 increases secretion ISO Gefitinib metabolite results in increased secretion of DNAJB1 protein CTD PMID:33132241 NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458 		JBrowse link
G Dusp3 dual specificity phosphatase 3 affects response to substance ISO DUSP3 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr10:86,920,014...86,933,739
Ensembl chr10:86,920,014...86,933,962 		JBrowse link
G Dusp9 dual specificity phosphatase 9 decreases expression ISO gefitinib results in decreased expression of DUSP9 mRNA CTD PMID:16685379 NCBI chr  X:151,351,897...151,355,822
Ensembl chr  X:151,351,897...151,355,821 		JBrowse link
G E2f1 E2F transcription factor 1 decreases expression ISO gefitinib results in decreased expression of E2F1 mRNA; gefitinib results in decreased expression of E2F1 protein CTD PMID:17094457 PMID:18347146 NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361 		JBrowse link
G Ednrb endothelin receptor type B multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of EDNRB mRNA] CTD PMID:18424623 NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115 		JBrowse link
G Egf epidermal growth factor multiple interactions ISO Gefitinib inhibits the reaction [EGF affects the localization of MAPK1]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK3]; Gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of RELA protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of STAT3 protein]; Gefitinib promotes the reaction [EGF protein binds to EGFR protein]; Gefitinib promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]; Gefitinib promotes the reaction [Resveratrol inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; Gefitinib promotes the reaction [Resveratrol inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; Resveratrol promotes the reaction [Gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; Resveratrol promotes the reaction [Gefitinib inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]
gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]		 CTD PMID:15841081 PMID:16243822 PMID:17805209 PMID:17898861 PMID:18927496 More... NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064 		JBrowse link
G Egfr epidermal growth factor receptor decreases response to substance
decreases activity
multiple interactions
decreases phosphorylation
decreases expression
increases response to substance
affects response to substance		 ISO
EXP		 EGFR gene mutant form results in decreased susceptibility to Gefitinib; EGFR protein mutant form results in decreased susceptibility to Gefitinib
Gefitinib results in decreased activity of EGFR protein
Gefitinib inhibits the reaction [astragaloside VI results in increased expression of and results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]]
Gefitinib results in decreased phosphorylation of EGFR protein
gefitinib results in decreased phosphorylation of EGFR protein
gefitinib results in decreased expression of EGFR protein modified form
[Gefitinib results in decreased activity of EGFR protein] which results in increased susceptibility to naphthalene; Gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [Folic Acid results in increased phosphorylation of EGFR protein]; Gefitinib promotes the reaction [Urethane results in increased phosphorylation of EGFR protein]; Gefitinib results in decreased phosphorylation of and results in decreased activity of EGFR protein; Methionine inhibits the reaction [Gefitinib promotes the reaction [Urethane results in increased phosphorylation of EGFR protein]]
Gefitinib results in decreased expression of EGFR protein modified form
[[Gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein] which results in decreased export of Doxorubicin; [cucurbitacin B co-treated with Gefitinib] results in decreased phosphorylation of EGFR protein; [Gefitinib co-treated with betulin] results in decreased expression of and results in decreased phosphorylation of EGFR protein; [Gefitinib co-treated with Oxaliplatin] results in decreased phosphorylation of EGFR protein; [Gefitinib promotes the reaction [EGFR protein binds to EGFR protein]] which results in decreased activity of EGFR protein; [Gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein; [ITGB1 protein results in increased activity of EGFR protein] which results in decreased susceptibility to Gefitinib; [Methionine co-treated with Gefitinib] results in decreased phosphorylation of EGFR protein; Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of EGFR protein modified form]; EGFR gene mutant form promotes the reaction [Gefitinib results in decreased expression of SQSTM1 protein]; EGFR gene mutant form promotes the reaction [Gefitinib results in increased cleavage of and results in increased activity of CASP3 protein]; Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]]; Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGFR protein results in decreased susceptibility to Docetaxel]; Gefitinib inhibits the reaction [Gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein]; Gefitinib inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [Irinotecan results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of EGFR mRNA]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of EGFR protein]; Gefitinib promotes the reaction [EGF protein binds to EGFR protein]; Gefitinib promotes the reaction [EGFR protein binds to EGFR protein]; Gefitinib promotes the reaction [IGF1R protein binds to EGFR protein]; Gefitinib results in decreased activity of [EGFR protein binds to EGFR protein]; Gefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein]; Gefitinib results in decreased expression of and results in decreased phosphorylation of EGFR protein; KRAS protein affects the reaction [EGFR protein affects the susceptibility to Gefitinib]; osimertinib inhibits the reaction [EGFR protein mutant form results in decreased susceptibility to Gefitinib]
EGFR gene mutant form results in increased susceptibility to gefitinib; EGFR gene polymorphism results in increased susceptibility to gefitinib; EGFR protein mutant form results in increased susceptibility to gefitinib
EGFR gene mutant form affects the susceptibility to Gefitinib; EGFR protein affects the susceptibility to Gefitinib; EGFR protein mutant form affects the susceptibility to Gefitinib		 CTD PMID:13680161 PMID:14679152 PMID:15660382 PMID:15723263 PMID:15841081 More... NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Epor erythropoietin receptor increases expression ISO gefitinib results in increased expression of EPOR mRNA CTD PMID:16685379 NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257 		JBrowse link
G Eps15 epidermal growth factor receptor pathway substrate 15 increases expression ISO gefitinib results in increased expression of EPS15 mRNA CTD PMID:16685379 NCBI chr 5:124,045,865...124,146,221
Ensembl chr 5:124,045,926...124,146,221 		JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions
decreases phosphorylation		 ISO gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein]; gefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein]
gefitinib results in decreased phosphorylation of ERBB2 protein		 CTD PMID:16243822 PMID:17898861 NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078 		JBrowse link
G Ercc1 ERCC excision repair 1, endonuclease non-catalytic subunit multiple interactions
affects response to substance		 ISO ERCC1 gene polymorphism affects the susceptibility to [gefitinib co-treated with Cisplatin]
ERCC1 gene polymorphism affects the susceptibility to gefitinib		 CTD PMID:21264830 NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963 		JBrowse link
G Esr1 estrogen receptor 1 decreases phosphorylation ISO gefitinib results in decreased phosphorylation of ESR1 protein CTD PMID:16261397 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002 		JBrowse link
G Esr2 estrogen receptor 2 increases expression
multiple interactions		 ISO gefitinib results in increased expression of ESR2 protein
Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]]		 CTD PMID:20005069 PMID:29383186 NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919 		JBrowse link
G Faslg Fas ligand multiple interactions
increases response to substance		 ISO benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Gefitinib results in increased susceptibility to FASLG protein] CTD PMID:31168030 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215 		JBrowse link
G Fgf6 fibroblast growth factor 6 increases expression ISO gefitinib results in increased expression of FGF6 mRNA CTD PMID:16685379 NCBI chr 4:159,854,913...159,863,447
Ensembl chr 4:159,854,913...159,863,447 		JBrowse link
G Fgfr3 fibroblast growth factor receptor 3 decreases expression ISO Gefitinib results in decreased expression of FGFR3 mRNA CTD PMID:38517198 NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341 		JBrowse link
G Fn1 fibronectin 1 multiple interactions ISO [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of FN1 protein CTD PMID:33248157 NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678 		JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of FOS mRNA] CTD PMID:36190352 NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036 		JBrowse link
G Foxf1 forkhead box F1 multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of FOXF1 mRNA] CTD PMID:18424623 NCBI chr19:49,153,949...49,157,741
Ensembl chr19:49,153,699...49,157,738 		JBrowse link
G Foxo3 forkhead box O3 increases response to substance
increases expression
multiple interactions		 ISO
EXP		 FOXO3 protein results in increased susceptibility to gefitinib
Gefitinib results in increased expression of FOXO3 mRNA; Gefitinib results in increased expression of FOXO3 protein; Gefitinib results in increased expression of FOXO3 protein modified form
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of FOXO3 mRNA]
gefitinib results in decreased phosphorylation of and affects the localization of FOXO3 protein		 CTD PMID:18089711 PMID:32370496 NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561 		JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha increases expression ISO gefitinib results in increased expression of GADD45A mRNA CTD PMID:16685379 NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115 		JBrowse link
G Gadd45g growth arrest and DNA-damage-inducible, gamma decreases expression ISO gefitinib results in decreased expression of GADD45G mRNA CTD PMID:16685379 NCBI chr17:13,376,842...13,378,587
Ensembl chr17:13,376,839...13,378,610 		JBrowse link
G Gars1 glycyl-tRNA synthetase 1 increases expression ISO Gefitinib results in increased expression of GARS1 mRNA CTD PMID:16685379 NCBI chr 4:84,171,596...84,212,609
Ensembl chr 4:84,171,596...84,212,609 		JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit affects response to substance ISO GCLC protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544 		JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions EXP gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased expression of GFAP protein]] CTD PMID:29228391 NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589 		JBrowse link
G Gnb2 G protein subunit beta 2 decreases expression ISO gefitinib results in decreased expression of GNB2 mRNA CTD PMID:16685379 NCBI chr12:19,159,002...19,164,021
Ensembl chr12:19,158,973...19,164,019 		JBrowse link
G Gnmt glycine N-methyltransferase multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of GNMT mRNA CTD PMID:20935109 NCBI chr 9:14,254,675...14,258,028
Ensembl chr 9:14,254,675...14,258,434 		JBrowse link
G Gper1 G protein-coupled estrogen receptor 1 multiple interactions ISO Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of GPER1 mRNA] CTD PMID:36190352 NCBI chr12:15,217,217...15,222,679
Ensembl chr12:15,217,442...15,221,889 		JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO Gefitinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta decreases expression ISO Gefitinib results in decreased expression of GSK3B protein modified form CTD PMID:30136359 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G Gucy2e guanylate cyclase 2E decreases expression ISO gefitinib results in decreased expression of GUCY2D mRNA CTD PMID:16685379 NCBI chr10:53,954,918...53,975,576
Ensembl chr10:53,959,010...53,974,067 		JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions ISO Gefitinib promotes the reaction [Folic Acid results in increased expression of HAVCR1 protein] CTD PMID:23255615 NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698 		JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions ISO
EXP		 gefitinib inhibits the reaction [irinotecan metabolite results in increased expression of HBEGF mRNA]; gefitinib inhibits the reaction [irinotecan results in increased expression of HBEGF mRNA]
gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased expression of GFAP protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased secretion of HBEGF protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in increased expression of and results in increased secretion of and results in increased activity of MMP9 protein]]		 CTD PMID:15723263 PMID:29228391 NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of HIF1A protein] CTD PMID:21544845 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261 		JBrowse link
G Hmgb1 high mobility group box 1 increases secretion ISO Gefitinib metabolite results in increased secretion of HMGB1 protein CTD PMID:33132241 NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565 		JBrowse link
G Hmox1 heme oxygenase 1 increases expression
multiple interactions		 EXP
ISO		 gefitinib results in increased expression of HMOX1 mRNA; gefitinib results in increased expression of HMOX1 protein
[Buthionine Sulfoximine co-treated with Gefitinib] results in increased expression of HMOX1 mRNA		 CTD PMID:27084042 PMID:32741899 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Hsp90aa1 heat shock protein 90 alpha family class A member 1 increases secretion ISO Gefitinib metabolite results in increased secretion of HSP90AA1 protein CTD PMID:33132241 NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268 		JBrowse link
G Hspa1a heat shock protein family A (Hsp70) member 1A increases secretion ISO Gefitinib metabolite results in increased secretion of HSPA1A protein CTD PMID:33132241 NCBI chr20:3,870,765...3,873,221
Ensembl chr20:3,856,006...3,873,227 		JBrowse link
G Htra1 HtrA serine peptidase 1 increases expression
multiple interactions		 ISO Gefitinib results in increased expression of HTRA1 mRNA
Arsenic inhibits the reaction [Gefitinib results in increased expression of HTRA1 mRNA]		 CTD PMID:36861143 NCBI chr 1:185,497,815...185,547,380
Ensembl chr 1:185,497,735...185,547,379 		JBrowse link
G Igf1 insulin-like growth factor 1 decreases secretion ISO Gefitinib results in decreased secretion of IGF1 protein CTD PMID:38517198 NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296 		JBrowse link
G Igf1r insulin-like growth factor 1 receptor multiple interactions
increases phosphorylation		 ISO gefitinib promotes the reaction [IGF1R protein binds to EGFR protein]; tyrphostin AG 1024 inhibits the reaction [gefitinib results in increased phosphorylation of IGF1R protein] CTD PMID:17473213 NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777 		JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases expression		 ISO gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of IL1B mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of IL1B protein]
Gefitinib metabolite results in increased expression of IL1B protein		 CTD PMID:23948867 PMID:33132241 NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415 		JBrowse link
G Itgam integrin subunit alpha M multiple interactions ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM protein]]; gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM mRNA]; gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM protein] CTD PMID:20226526 NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503 		JBrowse link
G Itgav integrin subunit alpha V multiple interactions ISO gefitinib inhibits the reaction [TNF protein results in increased expression of ITGAV mRNA] CTD PMID:15841081 NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639 		JBrowse link
G Itgb1 integrin subunit beta 1 multiple interactions ISO [ITGB1 protein results in increased activity of EGFR protein] which results in decreased susceptibility to gefitinib CTD PMID:21478906 NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195 		JBrowse link
G Kdr kinase insert domain receptor multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of KDR mRNA] CTD PMID:18424623 NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018 		JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 increases expression ISO gefitinib results in increased expression of KEAP1 mRNA CTD PMID:27639429 NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862 		JBrowse link
G Kras KRAS proto-oncogene, GTPase affects response to substance
decreases response to substance
multiple interactions		 ISO KRAS protein mutant form affects the susceptibility to gefitinib
KRAS protein results in decreased susceptibility to gefitinib
KRAS protein affects the reaction [EGFR protein affects the susceptibility to gefitinib]		 CTD PMID:17270025 PMID:28739874 NCBI chr 4:178,185,418...178,218,484 JBrowse link
G Lcn2 lipocalin 2 multiple interactions ISO Gefitinib promotes the reaction [Folic Acid results in increased expression of LCN2 protein] CTD PMID:23255615 NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095 		JBrowse link
G Lepr leptin receptor decreases expression ISO gefitinib results in decreased expression of LEPR mRNA CTD PMID:16685379 NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908 		JBrowse link
G Lgals9 galectin 9 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of LGALS9 mRNA CTD PMID:20935109 NCBI chr10:63,907,018...63,930,224
Ensembl chr10:63,907,018...63,930,045 		JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO [MIR578 affects the susceptibility to Gefitinib] which affects the lipidation of MAP1LC3B protein; SOCS2 protein affects the reaction [[MIR578 affects the susceptibility to Gefitinib] which affects the lipidation of MAP1LC3B protein] CTD PMID:37948135 NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation
decreases phosphorylation
decreases expression		 ISO
EXP		 Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK1]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [Promegestone results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of MAPK1 mRNA]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK1 protein]; Gefitinib promotes the reaction [[Zoledronic Acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased phosphorylation of MAPK1 protein]; Gefitinib results in decreased expression of and affects the phosphorylation of MAPK1 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of MAPK1 protein]; Methionine promotes the reaction [Gefitinib results in decreased phosphorylation of MAPK1 protein]
Gefitinib promotes the reaction [Urethane results in increased phosphorylation of MAPK1 protein]; Methionine inhibits the reaction [Gefitinib promotes the reaction [Urethane results in increased phosphorylation of MAPK1 protein]]
gefitinib results in increased phosphorylation of MAPK1 protein
gefitinib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of MAPK1 protein]
gefitinib results in decreased expression of MAPK1 protein modified form		 CTD PMID:15660382 PMID:16322342 PMID:17145836 PMID:17805209 PMID:17898861 More... NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
decreases expression
decreases phosphorylation		 ISO
EXP		 Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK3]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [Promegestone results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of MAPK3 mRNA]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK3 protein]; Gefitinib promotes the reaction [[Zoledronic Acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased phosphorylation of MAPK3 protein]; Gefitinib results in decreased expression of and affects the phosphorylation of MAPK3 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of MAPK3 protein]; Methionine promotes the reaction [Gefitinib results in decreased phosphorylation of MAPK3 protein]
Gefitinib promotes the reaction [Urethane results in increased phosphorylation of MAPK3 protein]; Methionine inhibits the reaction [Gefitinib promotes the reaction [Urethane results in increased phosphorylation of MAPK3 protein]]
gefitinib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of MAPK3 protein]
gefitinib results in increased phosphorylation of MAPK3 protein
gefitinib results in decreased expression of MAPK3 protein modified form		 CTD PMID:15660382 PMID:16322342 PMID:17145836 PMID:17805209 PMID:17898861 More... NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mapk6 mitogen-activated protein kinase 6 multiple interactions ISO Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of MAPK6 mRNA] CTD PMID:36190352 NCBI chr 8:76,146,650...76,169,767
Ensembl chr 8:76,146,690...76,169,720 		JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases phosphorylation
multiple interactions
decreases phosphorylation		 ISO gefitinib results in increased phosphorylation of MAPK8 protein
Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of MAPK8 mRNA]
Gefitinib results in decreased phosphorylation of MAPK8 protein		 CTD PMID:20846305 PMID:35317323 PMID:36190352 NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981 		JBrowse link
G Marveld1 MARVEL domain containing 1 decreases response to substance ISO MARVELD1 protein results in decreased susceptibility to Gefitinib CTD PMID:27447558 NCBI chr 1:240,954,050...240,958,101
Ensembl chr 1:240,954,452...240,958,384 		JBrowse link
G Mdk midkine multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in increased expression of MDK mRNA] CTD PMID:18424623 NCBI chr 3:77,901,134...77,903,997
Ensembl chr 3:77,901,158...77,903,130 		JBrowse link
G Micb MHC class I polypeptide-related sequence B increases expression ISO Gefitinib results in increased expression of MICB protein CTD PMID:21951556 NCBI chr 1:78,495,779...78,513,030
Ensembl chr 1:78,495,779...78,512,827 		JBrowse link
G Mill1 MHC I like leukocyte 1 increases expression ISO Gefitinib results in increased expression of MICA protein CTD PMID:21951556 NCBI chr 1:78,372,798...78,398,932
Ensembl chr 1:78,372,802...78,398,930 		JBrowse link
G Mki67 marker of proliferation Ki-67 multiple interactions ISO [Gefitinib co-treated with betulin] results in decreased expression of MKI67 protein CTD PMID:27447558 NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762 		JBrowse link
G Mlh1 mutL homolog 1 decreases expression ISO gefitinib results in decreased expression of MLH1 mRNA CTD PMID:16685379 NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617 		JBrowse link
G Mmp1 matrix metallopeptidase 1 decreases expression ISO Gefitinib results in decreased expression of MMP1 mRNA CTD PMID:38517198 NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097 		JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
decreases expression		 ISO
EXP		 gefitinib inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]
Gefitinib results in decreased expression of MMP9 mRNA; Gefitinib results in decreased expression of MMP9 protein
gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in increased expression of and results in increased secretion of and results in increased activity of MMP9 protein]]
gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 protein]; gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]		 CTD PMID:15841081 PMID:23127547 PMID:27087131 PMID:29228391 PMID:35317323 More... NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Mr1 major histocompatibility complex, class I-related affects expression ISO gefitinib affects the expression of MR1 mRNA CTD PMID:25811541 NCBI chr13:67,298,362...67,317,985
Ensembl chr13:67,299,585...67,317,970 		JBrowse link
G Mt2A metallothionein 2A multiple interactions ISO [Buthionine Sulfoximine co-treated with Gefitinib] results in increased expression of MT2 mRNA CTD PMID:32741899 NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784 		JBrowse link
G Mtor mechanistic target of rapamycin kinase decreases phosphorylation ISO gefitinib results in decreased phosphorylation of MTOR protein CTD PMID:21655094 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311 		JBrowse link
G Muc5ac mucin 5AC, oligomeric mucus/gel-forming multiple interactions ISO gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MUC5AC mRNA]; gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MUC5AC protein] CTD PMID:21544845 NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475 		JBrowse link
G Mug1 murinoglobulin 1 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of MUG1 mRNA CTD PMID:20935109 NCBI chr 4:155,076,270...155,130,051
Ensembl chr 4:155,076,312...155,130,051 		JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases expression ISO gefitinib results in decreased expression of MYC protein CTD PMID:17513607 NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630 		JBrowse link
G Myh7 myosin heavy chain 7 increases expression EXP gefitinib results in increased expression of MYH7 mRNA; gefitinib results in increased expression of MYH7 protein CTD PMID:27084042 NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217 		JBrowse link
G Ndufaf4 NADH:ubiquinone oxidoreductase complex assembly factor 4 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of NDUFAF4 mRNA CTD PMID:20935109 NCBI chr 5:38,605,169...38,610,341
Ensembl chr 5:38,605,153...38,610,336 		JBrowse link
G Nes nestin multiple interactions EXP Gefitinib inhibits the reaction [astragaloside VI results in increased expression of NES protein] CTD PMID:30088176 NCBI chr 2:173,437,867...173,447,777
Ensembl chr 2:173,438,734...173,447,777 		JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 decreases expression ISO gefitinib results in decreased expression of NFKB1 mRNA CTD PMID:16685379 NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404 		JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO [AURKA results in increased degradation of NFKBIA protein] which results in decreased susceptibility to gefitinib CTD PMID:21216229 NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941 		JBrowse link
G Nppa natriuretic peptide A increases expression
multiple interactions		 EXP Gefitinib results in increased expression of NPPA mRNA; Gefitinib results in increased expression of NPPA protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of NPPA mRNA]		 CTD PMID:32370496 NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351 		JBrowse link
G Nppb natriuretic peptide B increases expression EXP gefitinib results in increased expression of NPPB mRNA; gefitinib results in increased expression of NPPB protein CTD PMID:27084042 NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168 		JBrowse link
G Nptx2 neuronal pentraxin 2 decreases expression ISO gefitinib results in decreased expression of NPTX2 mRNA CTD PMID:16685379 NCBI chr12:10,037,435...10,048,345
Ensembl chr12:10,037,435...10,048,345 		JBrowse link
G Nrl neural retina leucine zipper decreases expression ISO gefitinib results in decreased expression of NRL mRNA CTD PMID:16685379 NCBI chr15:29,007,059...29,011,480
Ensembl chr15:29,008,104...29,009,832 		JBrowse link
G Osmr oncostatin M receptor affects response to substance ISO OSMR protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 2:55,907,119...55,961,373
Ensembl chr 2:55,907,132...55,961,262 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases expression
increases cleavage		 ISO Betulinic Acid promotes the reaction [Gefitinib results in increased cleavage of PARP1 protein]; Gefitinib affects the reaction [Oxaliplatin results in increased cleavage of PARP1 protein]
[Gefitinib results in increased secretion of CCL2 protein] inhibits the reaction [Gefitinib results in increased expression of PARP1 protein modified form]
gefitinib results in increased cleavage of PARP1 protein		 CTD PMID:16243822 PMID:23523951 PMID:30136359 PMID:33248157 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO Gefitinib inhibits the reaction [Folic Acid results in increased expression of PCNA protein] CTD PMID:23255615 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995 		JBrowse link
G Pcnt pericentrin decreases response to substance ISO PCNT protein results in decreased susceptibility to gefitinib CTD PMID:26298006 NCBI chr20:12,190,597...12,278,723
Ensembl chr20:12,191,648...12,278,710 		JBrowse link
G Pdzk1 PDZ domain containing 1 multiple interactions ISO Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of PDZK1 mRNA] CTD PMID:36190352 NCBI chr 2:184,376,161...184,407,514
Ensembl chr 2:184,376,161...184,407,514 		JBrowse link
G Pecam1 platelet and endothelial cell adhesion molecule 1 multiple interactions
decreases expression		 ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of PECAM1 mRNA]
Gefitinib results in decreased expression of PECAM1 protein		 CTD PMID:18424623 PMID:35317323 NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116 		JBrowse link
G Pgrmc1 progesterone receptor membrane component 1 decreases response to substance ISO PGRMC1 protein results in decreased susceptibility to gefitinib CTD PMID:26298006 NCBI chr  X:115,832,865...115,841,060
Ensembl chr  X:115,832,884...115,888,682 		JBrowse link
G Phlda2 pleckstrin homology-like domain, family A, member 2 affects response to substance ISO PHLDA2 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 1:198,696,897...198,699,292
Ensembl chr 1:198,696,897...198,697,836 		JBrowse link
G Plau plasminogen activator, urokinase multiple interactions ISO gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]] CTD PMID:23127547 NCBI chr15:3,456,230...3,462,732
Ensembl chr15:3,456,232...3,462,775 		JBrowse link
G Plbd1 phospholipase B domain containing 1 affects response to substance ISO PLBD1 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 4:169,472,983...169,529,277
Ensembl chr 4:169,472,983...169,529,277 		JBrowse link
G Pten phosphatase and tensin homolog multiple interactions
increases expression		 EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of PTEN mRNA]
Gefitinib results in increased expression of PTEN mRNA; Gefitinib results in increased expression of PTEN protein; Gefitinib results in increased expression of PTEN protein modified form		 CTD PMID:32370496 NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO gefitinib promotes the reaction [[zoledronic acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased expression of PTGS2 protein]
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of PTGS2 protein]		 CTD PMID:16322342 PMID:23948867 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Pttg1 PTTG1 regulator of sister chromatid separation, securin multiple interactions
decreases response to substance		 ISO gefitinib results in decreased stability of and results in decreased expression of PTTG1 protein
PTTG1 protein results in decreased susceptibility to gefitinib		 CTD PMID:23523951 NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837 		JBrowse link
G Qsox1 quiescin sulfhydryl oxidase 1 increases expression ISO gefitinib results in increased expression of QSOX1 mRNA CTD PMID:16685379 NCBI chr13:67,949,780...67,987,434
Ensembl chr13:67,949,780...67,987,459 		JBrowse link
G Rad51 RAD51 recombinase affects response to substance ISO RAD51 protein affects the susceptibility to Gefitinib CTD PMID:34998818 NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035 		JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions
decreases expression		 ISO Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of RB1 protein modified form]; Gefitinib promotes the reaction [Betulinic Acid results in decreased expression of RB1 protein modified form] CTD PMID:30136359 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302 		JBrowse link
G Rbm7 RNA binding motif protein 7 affects response to substance ISO RBM7 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 8:48,831,894...48,838,399
Ensembl chr 8:48,831,894...48,838,411 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
decreases response to substance		 ISO gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of RELA protein]
RELA protein results in decreased susceptibility to gefitinib		 CTD PMID:19318490 PMID:21216229 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Rpa1 replication protein A1 increases expression ISO gefitinib results in increased expression of RPA1 mRNA CTD PMID:16685379 NCBI chr10:60,148,869...60,199,970
Ensembl chr10:60,148,793...60,199,949 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 decreases phosphorylation ISO gefitinib results in decreased phosphorylation of RPS6KB1 protein CTD PMID:21655094 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908 		JBrowse link
G Rrm1 ribonucleotide reductase catalytic subunit M1 affects response to substance ISO RRM1 gene polymorphism affects the susceptibility to gefitinib CTD PMID:21264830 NCBI chr 1:156,823,960...156,848,262
Ensembl chr 1:156,823,960...156,848,261 		JBrowse link
G RT1-CE5 RT1 class I, locus CE5 affects expression ISO gefitinib affects the expression of HLA-F mRNA CTD PMID:25811541 NCBI chr20:3,403,418...3,479,476 JBrowse link
G RT1-Db1 RT1 class II, locus Db1 affects expression ISO gefitinib affects the expression of HLA-DRB1 mRNA CTD PMID:25811541 NCBI chr20:4,548,664...4,558,237
Ensembl chr20:4,548,666...4,558,258 		JBrowse link
G RT1-DOa RT1 class II, locus DOa affects expression ISO gefitinib affects the expression of HLA-DOA mRNA CTD PMID:25811541 NCBI chr20:4,753,587...4,756,590
Ensembl chr20:4,753,598...4,756,577 		JBrowse link
G S100a6 S100 calcium binding protein A6 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of S100A6 mRNA CTD PMID:20935109 NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180 		JBrowse link
G S100a8 S100 calcium binding protein A8 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of S100A8 mRNA; [gefitinib co-treated with naphthalene] affects the expression of S100A8 protein CTD PMID:20935109 NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643 		JBrowse link
G Serpinf1 serpin family F member 1 multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in increased expression of SERPINF1 mRNA] CTD PMID:18424623 NCBI chr10:60,250,198...60,262,593
Ensembl chr10:60,249,708...60,262,646 		JBrowse link
G Sfn stratifin decreases expression ISO gefitinib results in decreased expression of SFN mRNA CTD PMID:16685379 NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314 		JBrowse link
G Ski Ski proto-oncogene increases expression ISO gefitinib results in increased expression of SKI mRNA CTD PMID:16685379 NCBI chr 5:165,713,525...165,782,134
Ensembl chr 5:165,714,093...165,782,733 		JBrowse link
G Slc10a3 solute carrier family 10, member 3 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of SLC10A3 mRNA CTD PMID:20935109 NCBI chr  X:152,154,757...152,158,563
Ensembl chr  X:152,151,076...152,162,958 		JBrowse link
G Snai2 snail family transcriptional repressor 2 affects response to substance ISO SNAI2 protein affects the susceptibility to gefitinib CTD PMID:21037017 NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200 		JBrowse link
G Socs2 suppressor of cytokine signaling 2 decreases expression
multiple interactions		 ISO Gefitinib results in decreased expression of SOCS2 mRNA
SOCS2 protein affects the reaction [[MIR578 affects the susceptibility to Gefitinib] which affects the expression of BECN1 protein]; SOCS2 protein affects the reaction [[MIR578 affects the susceptibility to Gefitinib] which affects the expression of SQSTM1 protein]; SOCS2 protein affects the reaction [[MIR578 affects the susceptibility to Gefitinib] which affects the lipidation of MAP1LC3B protein]; SOCS2 protein affects the reaction [MIR578 affects the susceptibility to Gefitinib]		 CTD PMID:37948135 NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548 		JBrowse link
G Sox17 SRY-box transcription factor 17 decreases localization ISO gefitinib results in decreased localization of SOX17 protein CTD PMID:24154490 NCBI chr 5:15,016,660...15,022,228
Ensembl chr 5:15,016,731...15,022,228 		JBrowse link
G Sqstm1 sequestosome 1 multiple interactions
decreases expression		 ISO [Gefitinib co-treated with Cisplatin] results in decreased expression of SQSTM1 protein; [MIR578 affects the susceptibility to Gefitinib] which affects the expression of SQSTM1 protein; EGFR gene mutant form promotes the reaction [Gefitinib results in decreased expression of SQSTM1 protein]; SOCS2 protein affects the reaction [[MIR578 affects the susceptibility to Gefitinib] which affects the expression of SQSTM1 protein] CTD PMID:25979647 PMID:27639429 PMID:37948135 NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673 		JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO [Gefitinib co-treated with betulin] results in decreased expression of SREBF1 protein CTD PMID:27447558 NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650 		JBrowse link
G Srf serum response factor multiple interactions ISO Gefitinib inhibits the reaction [tetrachlorodian results in increased expression of SRF mRNA] CTD PMID:36190352 NCBI chr 9:14,426,453...14,435,734
Ensembl chr 9:14,426,472...14,435,733 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO [cucurbitacin B co-treated with Gefitinib] results in decreased phosphorylation of STAT3 protein; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of STAT3 protein]
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of STAT3 mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of STAT3 protein]		 CTD PMID:19318490 PMID:21787763 PMID:23948867 PMID:26183715 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057 		JBrowse link
G Synpo synaptopodin multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of SYNPO mRNA CTD PMID:20935109 NCBI chr18:54,048,299...54,106,388
Ensembl chr18:54,026,152...54,102,126 		JBrowse link
G Tek TEK receptor tyrosine kinase multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of TEK mRNA] CTD PMID:18424623 NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804 		JBrowse link
G Tert telomerase reverse transcriptase decreases expression ISO gefitinib results in decreased expression of TERT mRNA CTD PMID:17094457 NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561 		JBrowse link
G Tfap2a transcription factor AP-2 alpha multiple interactions ISO gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]] CTD PMID:21499124 PMID:21951556 NCBI chr17:24,028,716...24,047,507
Ensembl chr17:24,024,432...24,047,507 		JBrowse link
G Tgfa transforming growth factor alpha decreases response to substance
multiple interactions		 ISO TGFA protein results in decreased susceptibility to gefitinib
gefitinib inhibits the reaction [TGFA protein results in decreased expression of EDNRB mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of FOXF1 mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of KDR mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of PECAM1 mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of TEK mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of VEGFA mRNA]; gefitinib inhibits the reaction [TGFA protein results in increased expression of MDK mRNA]; gefitinib inhibits the reaction [TGFA protein results in increased expression of SERPINF1 mRNA]
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one promotes the reaction [gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]]; gefitinib inhibits the reaction [irinotecan metabolite results in increased secretion of TGFA protein]; gefitinib inhibits the reaction [irinotecan results in increased secretion of TGFA protein]; gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]		 CTD PMID:15723263 PMID:16230376 PMID:18424623 PMID:21266357 NCBI chr 4:118,618,043...118,700,897
Ensembl chr 4:118,618,269...118,700,894 		JBrowse link
G Tnf tumor necrosis factor multiple interactions
decreases expression		 ISO Gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of TNF mRNA]; Gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of TNF protein]; Gefitinib inhibits the reaction [TNF protein results in increased expression of ITGAV mRNA]; Gefitinib inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]
Gefitinib results in decreased expression of TNF mRNA
Gefitinib results in decreased expression of and results in decreased secretion of TNF protein		 CTD PMID:15841081 PMID:23948867 PMID:35317323 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Tnfrsf1b TNF receptor superfamily member 1B decreases expression ISO gefitinib results in decreased expression of TNFRSF1B mRNA CTD PMID:16685379 NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206 		JBrowse link
G Tnni3 troponin I3, cardiac type increases secretion EXP Gefitinib results in increased secretion of TNNI3 protein CTD PMID:32370496 NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580 		JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases expression
affects response to substance		 ISO
EXP		 [TP53 protein results in decreased expression of AURKA protein] which results in increased susceptibility to Gefitinib; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of TP53 protein]
gefitinib results in increased expression of TP53 mRNA; gefitinib results in increased expression of TP53 protein
TP53 protein affects the susceptibility to gefitinib		 CTD PMID:21216229 PMID:27084042 PMID:29383186 NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524 		JBrowse link
G Trim23 tripartite motif-containing 23 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of TRIM23 mRNA CTD PMID:20935109 NCBI chr 2:35,302,405...35,335,746
Ensembl chr 2:35,302,409...35,335,743 		JBrowse link
G Tsc22d1 TSC22 domain family, member 1 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of TSC22D1 mRNA CTD PMID:20935109 NCBI chr15:51,750,489...51,850,958
Ensembl chr15:51,749,510...51,850,958 		JBrowse link
G Twist1 twist family bHLH transcription factor 1 affects response to substance ISO TWIST1 protein affects the susceptibility to Gefitinib CTD PMID:30993382 NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653 		JBrowse link
G Tyms thymidylate synthetase decreases expression
multiple interactions		 ISO Gefitinib results in decreased expression of TYMS mRNA; Gefitinib results in decreased expression of TYMS protein
Betulinic Acid promotes the reaction [Gefitinib results in decreased expression of TYMS protein]; Gefitinib promotes the reaction [Betulinic Acid results in decreased expression of TYMS protein]; TYMS protein affects the susceptibility to [Gefitinib co-treated with S 1 (combination)]		 CTD PMID:18347146 PMID:30136359 NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536 		JBrowse link
G Ulbp1 UL16 binding protein 1 multiple interactions
increases expression		 ISO Gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]]; Tetradecanoylphorbol Acetate inhibits the reaction [Gefitinib results in increased expression of ULBP1 mRNA]
Gefitinib results in increased expression of ULBP1 mRNA; Gefitinib results in increased expression of ULBP1 protein		 CTD PMID:21499124 PMID:21951556 NCBI chr 1:1,694,255...1,716,160 JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions
decreases secretion
decreases expression		 ISO
EXP		 gefitinib inhibits the reaction [TGFA protein results in decreased expression of VEGFA mRNA]
Gefitinib results in decreased secretion of VEGFA protein
Gefitinib results in decreased expression of VEGFA mRNA; Gefitinib results in decreased expression of VEGFA protein
gefitinib results in decreased expression of VEGFA protein		 CTD PMID:15660382 PMID:18424623 PMID:35317323 PMID:38517198 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
G Vim vimentin multiple interactions
decreases expression		 ISO [Gefitinib results in increased secretion of CCL2 protein] which results in increased expression of VIM protein; Gefitinib inhibits the reaction [Folic Acid results in increased expression of VIM protein]
Gefitinib results in decreased expression of VIM protein		 CTD PMID:23255615 PMID:33248157 PMID:38517198 NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187 		JBrowse link
G Xrcc1 X-ray repair cross complementing 1 affects response to substance ISO XRCC1 protein polymorphism affects the susceptibility to gefitinib CTD PMID:21264830 NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701 		JBrowse link
G Zc3h3 zinc finger CCCH type containing 3 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of ZC3H3 mRNA CTD PMID:20935109 NCBI chr 7:107,440,694...107,525,451
Ensembl chr 7:107,440,694...107,525,451 		JBrowse link
IC-87114 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases phosphorylation		 ISO IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of AKT1 protein]
IC 87114 results in decreased phosphorylation of AKT1 protein		 CTD PMID:16179367 PMID:19176369 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions ISO IC 87114 inhibits the reaction [PTPN11 protein mutant form results in increased susceptibility to CSF2 protein] CTD PMID:22315502 NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199 		JBrowse link
G Foxo3 forkhead box O3 multiple interactions
decreases phosphorylation		 ISO IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of FOXO3 protein]
IC 87114 results in decreased phosphorylation of FOXO3 protein		 CTD PMID:16179367 NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561 		JBrowse link
G Gsk3a glycogen synthase kinase 3 alpha decreases phosphorylation ISO IC 87114 results in decreased phosphorylation of GSK3A protein CTD PMID:16179367 NCBI chr 1:80,815,843...80,825,732
Ensembl chr 1:80,815,850...80,825,802 		JBrowse link
G Gsk3b glycogen synthase kinase 3 beta decreases phosphorylation ISO IC 87114 results in decreased phosphorylation of GSK3B protein CTD PMID:16179367 NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646 		JBrowse link
G Il10 interleukin 10 multiple interactions ISO IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in decreased secretion of IL10 protein] CTD PMID:33711354 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il18 interleukin 18 multiple interactions ISO IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in increased secretion of IL18 protein] CTD PMID:33711354 NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887 		JBrowse link
G Il4 interleukin 4 multiple interactions ISO IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of AKT1 protein]; IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of FOXO3 protein]; IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of MAPK1 protein]; IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of MAPK3 protein]; IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in increased secretion of IL4 protein] CTD PMID:16179367 PMID:33711354 NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750 		JBrowse link
G Il5 interleukin 5 multiple interactions ISO IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in increased secretion of IL5 protein] CTD PMID:33711354 NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in increased secretion of IL6 protein] CTD PMID:33711354 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation		 ISO IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of MAPK1 protein]
IC 87114 results in decreased phosphorylation of MAPK1 protein		 CTD PMID:16179367 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation		 ISO IC 87114 inhibits the reaction [IL4 protein results in increased phosphorylation of MAPK3 protein]
IC 87114 results in decreased phosphorylation of MAPK3 protein		 CTD PMID:16179367 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Pik3cd phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta decreases activity
multiple interactions		 ISO IC 87114 results in decreased activity of PIK3CD protein
IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of PIK3CD protein]		 CTD PMID:16179367 PMID:33711354 NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930 		JBrowse link
G Pik3cg phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma multiple interactions ISO IC 87114 inhibits the reaction [Toluene 2,4-Diisocyanate results in increased expression of PIK3CG protein] CTD PMID:33711354 NCBI chr 6:48,766,778...48,802,098
Ensembl chr 6:48,766,864...48,802,043 		JBrowse link
G Ptpn11 protein tyrosine phosphatase, non-receptor type 11 multiple interactions
increases response to substance		 ISO IC 87114 inhibits the reaction [PTPN11 protein mutant form results in increased susceptibility to CSF2 protein]
PTPN11 protein mutant form results in increased susceptibility to IC 87114		 CTD PMID:22315502 NCBI chr12:35,365,436...35,424,925
Ensembl chr12:35,383,144...35,424,925 		JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 decreases phosphorylation ISO IC 87114 results in decreased phosphorylation of RPS6KB1 protein CTD PMID:16179367 NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908 		JBrowse link
idelalisib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases phosphorylation		 ISO [idelalisib co-treated with FASLG protein] results in decreased phosphorylation of AKT1 protein; AKT activator SC79 inhibits the reaction [[idelalisib co-treated with FASLG protein] results in decreased phosphorylation of AKT1 protein]; palbociclib promotes the reaction [idelalisib results in decreased phosphorylation of AKT1 protein] CTD PMID:23676220 PMID:31445927 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO [FASLG protein co-treated with idelalisib] results in increased expression of and affects the localization of BAX protein; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in increased expression of and affects the localization of BAX protein] CTD PMID:31445927 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator multiple interactions ISO [FASLG protein co-treated with idelalisib] results in decreased expression of BCL2 protein; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2 protein] CTD PMID:31445927 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Bcl2l1 Bcl2-like 1 multiple interactions ISO [FASLG protein co-treated with idelalisib] results in decreased expression of BCL2L1 protein; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2L1 protein] CTD PMID:31445927 NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479 		JBrowse link
G Bid BH3 interacting domain death agonist multiple interactions ISO [FASLG protein co-treated with idelalisib] results in increased cleavage of BID protein; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in increased cleavage of BID protein] CTD PMID:31445927 NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720 		JBrowse link
G Casp3 caspase 3 multiple interactions ISO [palbociclib results in increased susceptibility to idelalisib] which results in increased cleavage of CASP3 protein CTD PMID:23676220 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp8 caspase 8 multiple interactions ISO [TNF protein co-treated with idelalisib] results in increased activity of CASP8 protein; AKT activator SC79 inhibits the reaction [[TNF protein co-treated with idelalisib] results in increased activity of CASP8 protein]; AKT activator SC79 inhibits the reaction [idelalisib promotes the reaction [FASLG protein results in increased cleavage of CASP8 protein]]; idelalisib promotes the reaction [FASLG protein results in increased cleavage of CASP8 protein] CTD PMID:31445927 NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542 		JBrowse link
G Cflar CASP8 and FADD-like apoptosis regulator multiple interactions ISO [FASLG protein co-treated with idelalisib] results in decreased expression of CFLAR protein; [TNF protein co-treated with idelalisib] results in decreased expression of CFLAR protein; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of CFLAR protein]; AKT activator SC79 inhibits the reaction [[TNF protein co-treated with idelalisib] results in decreased expression of CFLAR protein] CTD PMID:31445927 NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034 		JBrowse link
G Cxcl1 C-X-C motif chemokine ligand 1 decreases expression ISO idelalisib decreases expression of Cxcl1 protein in liver and spleen RGD PMID:27999013 RGD:40890273 NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215 		JBrowse link
G Fas Fas cell surface death receptor affects response to substance
multiple interactions		 ISO idelalisib affects the susceptibility to FAS protein
FAS protein affects the reaction [idelalisib results in increased expression of ALT protein]		 CTD PMID:31445927 NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591 		JBrowse link
G Faslg Fas ligand multiple interactions ISO [FASLG protein co-treated with idelalisib] results in decreased expression of BCL2 protein; [FASLG protein co-treated with idelalisib] results in decreased expression of BCL2L1 protein; [FASLG protein co-treated with idelalisib] results in decreased expression of CFLAR protein; [FASLG protein co-treated with idelalisib] results in increased cleavage of BID protein; [FASLG protein co-treated with idelalisib] results in increased expression of and affects the localization of BAX protein; [idelalisib co-treated with FASLG protein] results in decreased phosphorylation of AKT1 protein; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2 protein]; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of BCL2L1 protein]; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in decreased expression of CFLAR protein]; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in increased cleavage of BID protein]; AKT activator SC79 inhibits the reaction [[FASLG protein co-treated with idelalisib] results in increased expression of and affects the localization of BAX protein]; AKT activator SC79 inhibits the reaction [[idelalisib co-treated with FASLG protein] results in decreased phosphorylation of AKT1 protein]; AKT activator SC79 inhibits the reaction [idelalisib inhibits the reaction [FASLG protein results in increased phosphorylation of RELA protein]]; AKT activator SC79 inhibits the reaction [idelalisib promotes the reaction [FASLG protein results in increased cleavage of CASP8 protein]]; idelalisib inhibits the reaction [FASLG protein results in increased phosphorylation of RELA protein]; idelalisib promotes the reaction [FASLG protein results in increased cleavage of CASP8 protein] CTD PMID:31445927 NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215 		JBrowse link
G Gpt glutamic--pyruvic transaminase multiple interactions
affects expression
increases expression		 ISO [Galactosamine co-treated with Lipopolysaccharides] promotes the reaction [idelalisib results in increased expression of ALT protein]; FAS protein affects the reaction [idelalisib results in increased expression of ALT protein]
idelalisib affects the expression of GPT protein		 CTD PMID:31445927 PMID:31501888 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha increases expression
multiple interactions		 ISO idelalisib results in increased expression of HIF1A protein
idelalisib inhibits the reaction [Lipopolysaccharides results in increased expression of HIF1A protein]		 CTD PMID:34978009 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261 		JBrowse link
G Ifng interferon gamma decreases expression ISO idelalisib decreases expression of Ifng protein in liver, spleen and lymph node RGD PMID:27999013 RGD:40890273 NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375 		JBrowse link
G Il10 interleukin 10 decreases expression ISO idelalisib decreases expression of Il10 protein in liver, lymph node and spleen RGD PMID:27999013 RGD:40890273 NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313 		JBrowse link
G Il4 interleukin 4 decreases expression ISO idelalisib decreases expression of Il4 protein in lymph node RGD PMID:27999013 RGD:40890273 NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750 		JBrowse link
G Il6 interleukin 6 decreases expression ISO idelalisib decreases expression of Il6 protein in liver and spleen RGD PMID:27999013 RGD:40890273 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Mir122 microRNA 122 affects expression ISO idelalisib affects the expression of MIR122 mRNA CTD PMID:31501888 NCBI chr18:58,758,703...58,758,787 JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions
decreases expression		 ISO idelalisib inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 mRNA]
idelalisib results in decreased expression of MMP9 protein		 CTD PMID:34978009 NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120 		JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions ISO idelalisib inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MTOR protein]
idelalisib inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MTOR protein]; idelalisib promotes the reaction [Lipopolysaccharides results in increased expression of MTOR mRNA]		 CTD PMID:34978009 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311 		JBrowse link
G Nat10 N-acetyltransferase 10 increases expression ISO idelalisib results in increased expression of NAT10 mRNA CTD PMID:35877022 NCBI chr 3:90,111,643...90,149,891
Ensembl chr 3:90,111,645...90,149,927 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions ISO [palbociclib results in increased susceptibility to idelalisib] which results in increased cleavage of PARP1 protein CTD PMID:23676220 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pik3ca phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha increases expression
multiple interactions		 ISO idelalisib results in increased expression of PIK3CA mRNA
idelalisib inhibits the reaction [TGFB1 protein results in increased expression of PIK3CA mRNA]		 CTD PMID:31522336 NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032 		JBrowse link
G Pik3cb phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta increases expression
multiple interactions		 ISO idelalisib results in increased expression of PIK3CB mRNA
idelalisib inhibits the reaction [TGFB1 protein results in increased expression of PIK3CB mRNA]		 CTD PMID:31522336 NCBI chr 8:99,594,600...99,699,772
Ensembl chr 8:99,594,644...99,699,663 		JBrowse link
G Pik3cd phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta multiple interactions
increases expression		 ISO idelalisib inhibits the reaction [TGFB1 protein results in decreased expression of PIK3CD mRNA]
idelalisib results in increased expression of PIK3CD mRNA		 CTD PMID:31522336 NCBI chr 5:160,094,952...160,142,962
Ensembl chr 5:160,094,952...160,120,930 		JBrowse link
G Pik3cg phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma decreases expression ISO idelalisib results in decreased expression of PIK3CG mRNA CTD PMID:31522336 NCBI chr 6:48,766,778...48,802,098
Ensembl chr 6:48,766,864...48,802,043 		JBrowse link
G Pik3ip1 phosphoinositide-3-kinase interacting protein 1 increases expression ISO idelalisib results in increased expression of PIK3IP1 mRNA CTD PMID:23676220 NCBI chr14:78,204,668...78,216,616
Ensembl chr14:78,204,053...78,216,608 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO AKT activator SC79 inhibits the reaction [idelalisib inhibits the reaction [FASLG protein results in increased phosphorylation of RELA protein]]; idelalisib inhibits the reaction [FASLG protein results in increased phosphorylation of RELA protein] CTD PMID:31445927 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO idelalisib inhibits the reaction [TGFB1 protein results in decreased expression of PIK3CD mRNA]; idelalisib inhibits the reaction [TGFB1 protein results in increased expression of PIK3CA mRNA]; idelalisib inhibits the reaction [TGFB1 protein results in increased expression of PIK3CB mRNA] CTD PMID:31522336 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Tnf tumor necrosis factor increases response to substance
multiple interactions		 ISO idelalisib results in increased susceptibility to TNF protein
[TNF protein co-treated with idelalisib] results in decreased expression of CFLAR protein; [TNF protein co-treated with idelalisib] results in increased activity of CASP8 protein; AKT activator SC79 inhibits the reaction [[TNF protein co-treated with idelalisib] results in decreased expression of CFLAR protein]; AKT activator SC79 inhibits the reaction [[TNF protein co-treated with idelalisib] results in increased activity of CASP8 protein]		 CTD PMID:31445927 NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629 		JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO idelalisib promotes the reaction [Lipopolysaccharides results in increased expression of VEGFA mRNA]
idelalisib inhibits the reaction [Lipopolysaccharides results in increased expression of VEGFA mRNA]; idelalisib inhibits the reaction [Lipopolysaccharides results in increased expression of VEGFA protein]		 CTD PMID:34978009 NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641 		JBrowse link
ketanserin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Adra1a adrenoceptor alpha 1A multiple interactions ISO
EXP		 Ketanserin inhibits the reaction [Prazosin binds to ADRA1A protein]
Ketanserin binds to and results in decreased activity of ADRA1A protein		 CTD PMID:11937776 PMID:16545797 NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500 		JBrowse link
G Adra1b adrenoceptor alpha 1B multiple interactions ISO Ketanserin inhibits the reaction [Prazosin binds to ADRA1B protein] CTD PMID:11937776 NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919 		JBrowse link
G Adra1d adrenoceptor alpha 1D multiple interactions ISO Ketanserin inhibits the reaction [Prazosin binds to ADRA1D protein] CTD PMID:11937776 NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO [[Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]] promotes the reaction [Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]]] which results in increased ubiquitination of and results in increased degradation of IRS1 protein; [Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]] promotes the reaction [Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]]; Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein] CTD PMID:22975078 NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Bdnf brain-derived neurotrophic factor multiple interactions EXP [Fluoxetine co-treated with Ketanserin] results in increased expression of BDNF mRNA CTD PMID:21627639 NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615 		JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions EXP [Fluoxetine co-treated with Ketanserin] results in increased expression of CTNNB1 mRNA CTD PMID:21627639 NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111 		JBrowse link
G Ddc dopa decarboxylase increases activity ISO Ketanserin results in increased activity of DDC protein CTD PMID:16415089 NCBI chr14:86,378,685...86,469,189
Ensembl chr14:86,378,685...86,469,208 		JBrowse link
G Htr2a 5-hydroxytryptamine receptor 2A multiple interactions
decreases activity
affects binding		 ISO
EXP		 Aripiprazole inhibits the reaction [Ketanserin binds to HTR2A protein]; Clozapine inhibits the reaction [Ketanserin binds to HTR2A protein]; Ketanserin binds to and results in decreased activity of HTR2A protein; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Ketanserin binds to HTR2A protein]; Quetiapine Fumarate inhibits the reaction [Ketanserin binds to HTR2A protein]; Spiperone inhibits the reaction [Ketanserin binds to HTR2A protein]; ziprasidone inhibits the reaction [Ketanserin binds to HTR2A protein]
Ketanserin results in decreased activity of HTR2A protein
8-fluoro-12-(4-methylpiperazin-1-yl)-6H-(1)benzothieno(2,3-b)(1,5)benzodiazepine inhibits the reaction [Ketanserin binds to HTR2A protein]; [Ketanserin binds to and results in decreased activity of HTR2A protein] inhibits the reaction [Methamphetamine results in decreased abundance of Serotonin]; [Ketanserin binds to and results in decreased activity of HTR2A protein] inhibits the reaction [Methamphetamine results in increased secretion of Corticosterone]; [Ketanserin binds to and results in decreased activity of HTR2A protein] which results in decreased susceptibility to Serotonin; Diazinon promotes the reaction [Ketanserin binds to HTR2A protein]; Ketanserin binds to and results in decreased activity of HTR2A protein; Ketanserin inhibits the reaction [[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine]; Ketanserin inhibits the reaction [Cocaine promotes the reaction [[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine]]; Ketanserin inhibits the reaction [Tramadol results in increased activity of HTR2A protein]; Risperidone inhibits the reaction [Ketanserin binds to HTR2A protein]
4-iodo-2,5-dimethoxyphenylisopropylamine inhibits the reaction [Ketanserin binds to HTR2A protein]; cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester inhibits the reaction [Ketanserin binds to HTR2A protein]; HU 211 inhibits the reaction [Ketanserin binds to HTR2A protein]; Ketanserin binds to and results in decreased activity of HTR2A protein		 CTD PMID:2891550 PMID:10773215 PMID:10978843 PMID:11927170 PMID:16314884 More... NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928 		JBrowse link
G Htr7 5-hydroxytryptamine receptor 7 multiple interactions ISO [Ketanserin binds to and results in decreased activity of HTR7 protein] inhibits the reaction [5-carboxamidotryptamine results in increased abundance of Cyclic AMP] CTD PMID:14578406 NCBI chr 1:233,636,442...233,761,063
Ensembl chr 1:233,636,452...233,760,626 		JBrowse link
G Il6 interleukin 6 multiple interactions ISO Ketanserin inhibits the reaction [Serotonin results in increased expression of and results in increased secretion of IL6 protein] CTD PMID:11076827 NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178 		JBrowse link
G Irs1 insulin receptor substrate 1 multiple interactions ISO [[Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]] promotes the reaction [Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]]] which results in increased ubiquitination of and results in increased degradation of IRS1 protein; [Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]] promotes the reaction [Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]] CTD PMID:22975078 NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO Ketanserin inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK1 protein] CTD PMID:22048642 NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO Ketanserin inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK3 protein] CTD PMID:22048642 NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions ISO Ketanserin inhibits the reaction [Tobacco Smoke Pollution affects the localization of NFE2L2 protein] CTD PMID:22048642 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Ppp1r1b protein phosphatase 1, regulatory (inhibitor) subunit 1B multiple interactions ISO Ketanserin inhibits the reaction [Serotonin results in increased phosphorylation of PPP1R1B protein] CTD PMID:11880652 NCBI chr10:83,347,731...83,356,775
Ensembl chr10:83,347,731...83,356,775 		JBrowse link
G Slc6a4 solute carrier family 6 member 4 affects binding
multiple interactions		 ISO Ketanserin binds to SLC6A4 protein
methamidophos inhibits the reaction [Ketanserin binds to SLC6A4 protein]		 CTD PMID:21871486 NCBI chr10:61,824,208...61,858,924
Ensembl chr10:61,826,123...61,858,384 		JBrowse link
G Ywhab tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, beta multiple interactions ISO [[Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]] promotes the reaction [Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]]] which results in increased ubiquitination of and results in increased degradation of IRS1 protein; [Ketanserin inhibits the reaction [Serotonin results in increased activity of AKT1 protein]] promotes the reaction [Serotonin inhibits the reaction [IRS1 protein binds to YWHAB protein]] CTD PMID:22975078 NCBI chr 3:152,659,663...152,682,105
Ensembl chr 3:152,659,651...152,682,105 		JBrowse link
lapatinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO lapatinib results in decreased activity of ABCB11 protein CTD PMID:20829430 PMID:23956101 PMID:28437613 NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730 		JBrowse link
G Abcb1a ATP binding cassette subfamily B member 1A multiple interactions ISO lapatinib inhibits the reaction [ABCB1 protein results in increased export of and results in decreased susceptibility to Doxorubicin]; lapatinib inhibits the reaction [azidoprazosin binds to ABCB1 protein]; lapatinib promotes the reaction [ABCB1 protein results in increased hydrolysis of Adenosine Triphosphate] CTD PMID:18829547 NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709 		JBrowse link
G Abcb4 ATP binding cassette subfamily B member 4 decreases activity ISO lapatinib results in decreased activity of ABCB4 protein CTD PMID:28437613 NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202 		JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO lapatinib inhibits the reaction [ABCG2 gene mutant form results in increased export of and results in decreased susceptibility to Mitoxantrone]; lapatinib inhibits the reaction [ABCG2 protein results in decreased susceptibility to Topotecan]; lapatinib inhibits the reaction [ABCG2 protein results in increased export of and results in decreased susceptibility to Mitoxantrone]; lapatinib inhibits the reaction [ABCG2 protein results in increased export of Methotrexate]; lapatinib inhibits the reaction [ABCG2 protein results in increased transport of estradiol-17 beta-glucuronide]; lapatinib inhibits the reaction [azidoprazosin binds to ABCG2 protein]; lapatinib promotes the reaction [ABCG2 protein results in increased hydrolysis of Adenosine Triphosphate] CTD PMID:18829547 NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409 		JBrowse link
G Acta2 actin alpha 2, smooth muscle multiple interactions ISO [lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ACTA2 protein; Niclosamide inhibits the reaction [[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ACTA2 protein] CTD PMID:26643609 NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554 		JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases phosphorylation
decreases activity
decreases expression		 ISO [Bortezomib co-treated with Lapatinib] results in decreased phosphorylation of AKT1 protein; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of AKT1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of AKT1 protein]
Lapatinib results in decreased phosphorylation of AKT1 protein
lapatinib results in decreased activity of AKT1 protein
lapatinib results in decreased expression of AKT1 protein; lapatinib results in decreased expression of AKT1 protein modified form		 CTD PMID:15665275 PMID:16091755 PMID:19435893 PMID:19509167 PMID:20701607 More... NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921 		JBrowse link
G Aldh1a1 aldehyde dehydrogenase 1 family, member A1 multiple interactions ISO [lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of ALDH1A1 protein CTD PMID:26643609 NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961 		JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression
multiple interactions		 ISO Lapatinib results in increased expression of BAX protein
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased expression of BAX protein]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BAX protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BAX protein]]		 CTD PMID:29387217 PMID:32890875 NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368 		JBrowse link
G Bcl2 BCL2, apoptosis regulator decreases expression
multiple interactions		 ISO Lapatinib results in decreased expression of BCL2 protein
AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of BCL2 protein]]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of BCL2 protein]]		 CTD PMID:29387217 PMID:32890875 NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743 		JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 decreases expression ISO lapatinib results in decreased expression of BIRC5 protein CTD PMID:16091755 NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380 		JBrowse link
G Bnip3 BCL2 interacting protein 3 multiple interactions ISO Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; Lapatinib inhibits the reaction [concanamycin A results in increased expression of BNIP3 mRNA] CTD PMID:25981168 NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359 		JBrowse link
G Casp3 caspase 3 increases cleavage
increases activity
multiple interactions		 ISO Lapatinib results in increased cleavage of CASP3 protein
Lapatinib results in increased activity of CASP3 protein
2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of CASP3 protein]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CASP3 protein]]		 CTD PMID:29387217 PMID:32890875 PMID:37788138 NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648 		JBrowse link
G Casp7 caspase 7 increases activity ISO Lapatinib results in increased activity of CASP7 protein CTD PMID:37788138 NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:255,437,172...255,476,729 		JBrowse link
G Casp9 caspase 9 multiple interactions
increases activity
increases cleavage		 ISO 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of CASP9 protein]
Lapatinib results in increased activity of CASP9 protein		 CTD PMID:29387217 PMID:37788138 NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626 		JBrowse link
G Ccna2 cyclin A2 decreases expression ISO lapatinib results in decreased expression of CCNA2 protein CTD PMID:25221644 NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577 		JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression		 ISO [afimoxifene co-treated with Lapatinib] results in decreased expression of CCND1 protein; [Genistein co-treated with Lapatinib] affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of CCND1 protein]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of CCND1 protein]; Lapatinib affects the reaction [CXCL8 protein affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of CCND1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein]]
lapatinib results in decreased expression of CCND1 protein		 CTD PMID:15665275 PMID:25221644 PMID:32890875 PMID:33396024 NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602 		JBrowse link
G Ccne1 cyclin E1 multiple interactions ISO [afimoxifene co-treated with lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]] CTD PMID:15665275 NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101 		JBrowse link
G Cd24 CD24 molecule multiple interactions ISO [lapatinib results in decreased susceptibility to lapatinib] which results in decreased expression of CD24 protein CTD PMID:26643609 NCBI chr20:47,074,353...47,079,662
Ensembl chr20:47,073,512...47,079,662 		JBrowse link
G Cd44 CD44 molecule multiple interactions ISO [Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of CD44 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of CD44 protein]] CTD PMID:26643609 PMID:33396024 NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620 		JBrowse link
G Cdh1 cadherin 1 multiple interactions ISO [Genistein co-treated with Lapatinib] promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in decreased expression of CDH1 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of CDH1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of CDH1 protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in decreased expression of CDH1 protein] CTD PMID:26643609 PMID:32890875 PMID:33396024 NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775 		JBrowse link
G Cdh2 cadherin 2 multiple interactions ISO [lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of CDH2 protein; Niclosamide inhibits the reaction [[lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of CDH2 protein] CTD PMID:26643609 NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167 		JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions ISO [afimoxifene co-treated with lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]] CTD PMID:15665275 NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403 		JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO Lapatinib inhibits the reaction [sodium arsenite results in increased expression of CDKN1A protein] CTD PMID:32890875 NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585 		JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
increases expression		 ISO [afimoxifene co-treated with Lapatinib] promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]; [afimoxifene co-treated with Lapatinib] results in increased expression of CDKN1B protein; Bortezomib promotes the reaction [Lapatinib results in increased expression of CDKN1B protein]; Lapatinib inhibits the reaction [sodium arsenite results in decreased expression of CDKN1B protein]; Lapatinib promotes the reaction [Bortezomib results in increased expression of CDKN1B protein]; Lapatinib promotes the reaction [CDKN1B protein binds to and results in decreased activity of [CCNE1 protein binds to CDK2 protein]]
lapatinib results in increased expression of CDKN1B protein		 CTD PMID:15665275 PMID:20701607 PMID:32890875 NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982 		JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 decreases activity
increases metabolic processing		 ISO Lapatinib results in decreased activity of CYP1A1 protein
CYP1A1 protein results in increased metabolism of Lapatinib		 CTD PMID:33814510 PMID:37788138 NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125 		JBrowse link
G Cyp1b1 cytochrome P450, family 1, subfamily b, polypeptide 1 decreases activity ISO Lapatinib results in decreased activity of CYP1B1 protein CTD PMID:33814510 NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917 		JBrowse link
G Cyp3a2 cytochrome P450, family 3, subfamily a, polypeptide 2 increases metabolic processing
multiple interactions		 ISO CYP3A4 protein results in increased metabolism of Lapatinib
[CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased activity of NFE2L2 protein; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of HMOX1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of NQO1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of SOD1 mRNA; [CYP3A4 protein results in increased metabolism of Lapatinib] which results in increased expression of SOD2 mRNA		 CTD PMID:26958860 PMID:33259822 PMID:37788138 NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008 		JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 increases metabolic processing
multiple interactions		 ISO CYP3A5 protein results in increased metabolism of Lapatinib
[CYP3A5 protein results in increased metabolism of Lapatinib] which results in increased activity of NFE2L2 protein; CYP3A5 protein inhibits the reaction [Lapatinib results in increased expression of H2AX protein]		 CTD PMID:26958860 PMID:37788138 NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422 		JBrowse link
G Egfr epidermal growth factor receptor decreases activity
affects response to substance
multiple interactions		 ISO lapatinib results in decreased activity of EGFR protein
EGFR protein affects the susceptibility to lapatinib
KRAS protein affects the reaction [EGFR protein affects the susceptibility to lapatinib]; lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]; lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]]		 CTD PMID:15665275 PMID:17192538 PMID:19509167 PMID:20549698 PMID:28739874 NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382 		JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions
decreases phosphorylation
decreases expression
decreases activity		 ISO [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of ERBB2 protein; Bortezomib promotes the reaction [Lapatinib results in decreased phosphorylation of ERBB2 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK1 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK3 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of CCND1 protein]; ERBB2 protein affects the reaction [Lapatinib results in decreased expression of MCM7 protein]; Lapatinib promotes the reaction [Bortezomib results in decreased phosphorylation of ERBB2 protein]
lapatinib results in decreased phosphorylation of ERBB2 protein
lapatinib results in decreased expression of ERBB2 protein
lapatinib results in decreased activity of ERBB2 protein		 CTD PMID:15665275 PMID:16091755 PMID:17192538 PMID:19509167 PMID:20197467 More... NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078 		JBrowse link
G Erbb3 erb-b2 receptor tyrosine kinase 3 decreases expression
decreases activity		 ISO lapatinib results in decreased expression of ERBB3 protein modified form
lapatinib results in decreased activity of ERBB3 protein		 CTD PMID:19435893 PMID:19509167 NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525 		JBrowse link
G Esr1 estrogen receptor 1 decreases activity
multiple interactions		 ISO lapatinib results in decreased activity of ESR1 protein
[lapatinib co-treated with afimoxifene] results in decreased activity of ESR1 protein		 CTD PMID:15665275 NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002 		JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO Lapatinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494 		JBrowse link
G H2ax H2A.X variant histone increases expression
multiple interactions		 ISO Lapatinib results in increased expression of H2AX protein
CYP3A5 protein inhibits the reaction [Lapatinib results in increased expression of H2AX protein]; CYP3A7 protein inhibits the reaction [Lapatinib results in increased expression of H2AX protein]		 CTD PMID:37788138 NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239 		JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]]; Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of HIF1A protein]; Lapatinib inhibits the reaction [concanamycin A results in increased expression of HIF1A protein]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of HIF1A protein]] CTD PMID:25981168 PMID:32890875 NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261 		JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions
increases expression		 ISO [CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of HMOX1 mRNA
lapatinib metabolite results in increased expression of HMOX1 mRNA		 CTD PMID:26958860 NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079 		JBrowse link
G Jak2 Janus kinase 2 multiple interactions ISO Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of JAK2 protein] CTD PMID:32890875 NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189 		JBrowse link
G Kras KRAS proto-oncogene, GTPase decreases response to substance
multiple interactions		 ISO KRAS protein results in decreased susceptibility to lapatinib
KRAS protein affects the reaction [EGFR protein affects the susceptibility to lapatinib]		 CTD PMID:28739874 NCBI chr 4:178,185,418...178,218,484 JBrowse link
G Ldha lactate dehydrogenase A increases secretion ISO Lapatinib results in increased secretion of LDHA protein CTD PMID:37660997 NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472 		JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
decreases expression
decreases activity		 ISO ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK1 protein]; Lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK1 protein]
lapatinib results in decreased phosphorylation of MAPK1 protein
lapatinib results in decreased expression of MAPK1 protein
lapatinib results in decreased activity of MAPK1 protein		 CTD PMID:16091755 PMID:20701607 PMID:22233293 PMID:25221644 PMID:32890875 More... NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616 		JBrowse link
G Mapk12 mitogen-activated protein kinase 12 multiple interactions ISO lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to MAPK12 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to MAPK12 protein]] CTD PMID:28739874 NCBI chr 7:120,206,005...120,216,711
Ensembl chr 7:120,206,271...120,216,664 		JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
decreases expression
decreases activity		 ISO ERBB2 protein affects the reaction [Lapatinib results in decreased activity of MAPK3 protein]; Lapatinib inhibits the reaction [Bortezomib results in increased phosphorylation of MAPK3 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK3 protein]
lapatinib results in decreased phosphorylation of MAPK3 protein
lapatinib results in decreased expression of MAPK3 protein
lapatinib results in decreased activity of MAPK3 protein		 CTD PMID:16091755 PMID:20701607 PMID:22233293 PMID:25221644 PMID:32890875 More... NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863 		JBrowse link
G Mcm7 minichromosome maintenance complex component 7 multiple interactions
decreases expression		 ISO ERBB2 protein affects the reaction [lapatinib results in decreased expression of MCM7 protein] CTD PMID:25221644 NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063 		JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions ISO [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of MTOR protein; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of MTOR protein] CTD PMID:26643609 NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311 		JBrowse link
G Nfe2l2 NFE2 like bZIP transcription factor 2 multiple interactions
increases activity		 ISO [CYP3A4 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein; [CYP3A5 protein results in increased metabolism of lapatinib] which results in increased activity of NFE2L2 protein
lapatinib metabolite results in increased activity of NFE2L2 protein		 CTD PMID:26958860 NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737 		JBrowse link
G Nqo1 NAD(P)H quinone dehydrogenase 1 multiple interactions
increases expression		 ISO [CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of NQO1 mRNA
lapatinib metabolite results in increased expression of NQO1 mRNA		 CTD PMID:26958860 NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557 		JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage		 ISO 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole inhibits the reaction [Lapatinib results in increased cleavage of PARP1 protein]; [Lapatinib co-treated with bafilomycin A] results in increased cleavage of PARP1 protein; [Lapatinib co-treated with concanamycin A] results in increased cleavage of PARP1 protein; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in decreased cleavage of PARP1 protein]] CTD PMID:25221644 PMID:25981168 PMID:29387217 PMID:32890875 NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404 		JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO [Genistein co-treated with Lapatinib] affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of PCNA protein]; AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]]; Lapatinib affects the reaction [CXCL8 protein affects the reaction [[sodium arsenite results in increased abundance of Arsenic] which affects the expression of PCNA protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PCNA protein]] CTD PMID:32890875 PMID:33396024 NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995 		JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO AKT activator SC79 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]; SB 203580 inhibits the reaction [Lapatinib inhibits the reaction [sodium arsenite results in increased expression of PTGS2 protein]] CTD PMID:32890875 NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188 		JBrowse link
G Ptpn3 protein tyrosine phosphatase, non-receptor type 3 multiple interactions ISO lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]; lapatinib promotes the reaction [pirfenidone inhibits the reaction [EGFR protein binds to PTPN3 protein]]; pirfenidone promotes the reaction [lapatinib inhibits the reaction [EGFR protein binds to PTPN3 protein]] CTD PMID:28739874 NCBI chr 5:71,908,520...72,027,323
Ensembl chr 5:71,911,135...72,065,443 		JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase multiple interactions ISO Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of RAF1 protein] CTD PMID:32890875 NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317 		JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions ISO Lapatinib inhibits the reaction [sodium arsenite results in decreased phosphorylation of RB1 protein] CTD PMID:32890875 NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302 		JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of RELA protein; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of RELA protein] CTD PMID:26643609 NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484 		JBrowse link
G Snai1 snail family transcriptional repressor 1 multiple interactions
decreases response to substance		 ISO [Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]; [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of SNAI1 protein; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased expression of SNAI1 protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased expression of SNAI1 protein]
SNAI1 protein results in decreased susceptibility to lapatinib		 CTD PMID:26643609 PMID:32890875 PMID:33396024 NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969 		JBrowse link
G Snai2 snail family transcriptional repressor 2 multiple interactions ISO [Genistein co-treated with Lapatinib] inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 mRNA]; Lapatinib inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 mRNA]]; Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI2 protein]] CTD PMID:33396024 NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200 		JBrowse link
G Sod1 superoxide dismutase 1 multiple interactions ISO [CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of SOD1 mRNA CTD PMID:26958860 NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249 		JBrowse link
G Sod2 superoxide dismutase 2 multiple interactions
increases expression		 ISO [CYP3A4 protein results in increased metabolism of lapatinib] which results in increased expression of SOD2 mRNA
lapatinib metabolite results in increased expression of SOD2 mRNA		 CTD PMID:26958860 NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189 		JBrowse link
G Sox2 SRY-box transcription factor 2 multiple interactions ISO [lapatinib results in decreased susceptibility to lapatinib] which results in increased expression of SOX2 protein CTD PMID:26643609 NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338 		JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions ISO [Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of SRC protein; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of SRC protein]; Niclosamide inhibits the reaction [[Lapatinib results in decreased susceptibility to Lapatinib] which results in increased phosphorylation of SRC protein] CTD PMID:26643609 PMID:32890875 NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476 		JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO Lapatinib inhibits the reaction [CXCL8 protein promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of STAT3 protein]]; Lapatinib inhibits the reaction [sodium arsenite results in increased phosphorylation of STAT3 protein] CTD PMID:32890875 PMID:33396024 NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057 		JBrowse link
G Tgfb1 transforming growth factor, beta 1 decreases response to substance ISO TGFB1 protein results in decreased susceptibility to lapatinib CTD PMID:26643609 NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847 		JBrowse link
G Top1 DNA topoisomerase I decreases expression ISO Lapatinib results in decreased expression of TOP1 protein CTD PMID:37788138 NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623 		JBrowse link